The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

8-2010

ARTEMIS INTERACTS WITH THE CUL4A UBIQUITIN E3 LIGASE
COMPLEX AND REGULATES THE CELL CYCLE PROGRESSION
Yiyi Yan

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Cell and Developmental Biology Commons, and the Molecular Biology Commons

Recommended Citation
Yan, Yiyi, "ARTEMIS INTERACTS WITH THE CUL4A UBIQUITIN E3 LIGASE COMPLEX AND REGULATES
THE CELL CYCLE PROGRESSION" (2010). The University of Texas MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 60.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/60

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

ARTEMIS INTERACTS WITH THE CUL4A UBIQUITIN E3 LIGASE
COMPLEX AND REGULATES THE CELL CYCLE PROGRESSION

By
Yiyi Yan
M.D, M.S

APPROVED:

Dr. Randy J. Legerski, Supervisory Professor

Dr. Michael Andreeff

Dr. Elsa Flores

Dr. Mong-Hong Lee

Dr. Lei Li

APPROVED:

Dean, The University of Texas
Health Science Center at Houston
Graduate School of Biomedical Science

ARTEMIS INTERACTS WITH THE CUL4A UBIQUITIN E3 LIGASE
COMPLEX AND REGULATES THE CELL CYCLE PROGRESSION

A
DISSERTATION

Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
M. D. Anderson Cancer Center
Graduate School of Biomedical Science
in Partial Fulfillment
of the Requirements
for the Degree of
Doctor of Philosophy

by
Yiyi Yan
M.D, M.S
Houston, Texas
August, 2010
Copyright © 2010 Yiyi Yan
All rights reserved

ACKNOWLEDGEMENTS

There are several individuals whom I would like to take this opportunity to thank. I
would like to thank my family for their support along my way to becoming a scientist. I
owe thanks to the faculties who had served and are serving on my committee, Dr. Lei Li,
Dr. Mong-Hong Lee, Dr. Michael Andreeff, Dr. Elsa Flores, Dr. Sanka Maity, and Dr.
Michael Siciliano for their years of guidance. I also want to acknowledge the members
of Dr. Legerski’s laboratory: Xiaoshan Zhang, Shamima Akhter, Xiaoyan Lu, Lingling
Liu and Janice Succi. In additional, I would like to thank all the laboratories that
provided me with unique reagents (antibodies and plasmids). Finally, I would like to
thank Dr. Randy Legerski, who has served as my mentor and advisor in this research
endeavor. His commitment and dedication to research are an inspiration, and it is only
with his support and guidance that this work has been possible.

iii

ARTEMIS INTERACTS WITH THE CUL4A UBIQUITIN E3 LIGASE
COMPLEX AND REGULATES THE CELL CYCLE PROGRESSION

Publication No.

Yiyi Yan, M.D, M.S

Supervisory Professor: Randy Legerski, Ph.D.

Artemis, a member of the SNM1 gene family, is one of the six known components of
the non-homologous end joining pathway. It is a multifunctional phospho-protein that
has been shown to be modified by the phosphatidylinositol 3-kinases (PIKs) DNA-PKcs,
ATM and ATR in response to a variety of cellular stresses. Artemis has important roles
in V(D)J recombination, DNA double strand breaks repair and damage-induced cellcycle checkpoint regulation. The detailed mechanism by which Artemis mediates its
functions in these cellular pathways needs to be further elucidated. My work presented
here demonstrates a new function for Artemis in cell cycle regulation as a component of
Cullin-based E3 ligase complex. I show that Artemis interacts with Cul4A-DDB1 ligase
complex via a direct interaction with the substrate-specific receptor DDB2, and deletion
mapping analysis shows that part of the Snm1 domain of Artemis is responsible for this
interaction. Additionally, Artemis also interacts with p27, a substrate of Cul4A-DDB1
complex, and both DDB2 and Artemis are required for the degradation of p27 mediated
by this complex. Furthermore, I show that the regulation of p27 by Artemis and DDB2 is
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critical for cell cycle progression in normally proliferating cells and in response to serum
withdrawal. Finally, I provide evidence showing that Artemis may be also a part of other
Cullin-based E3 ligase complexes, and it has a role in controlling p27 levels in response
to different cellular stress, such as UV irradiation. These findings suggest a novel
pathway to regulate p27 protein level and define a new function for Artemis as an
effector of Cullin-based E3-ligase mediated ubiquitylation, and thus, a cell cycle
regulator in proliferating cells.
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Chapter I. Introduction

1

Severe Combined Immunodeficiency (SCID)

Severe combined Immunodeficiency is a group of heritable disorders in which both
T cell and B cell maturation are severely affected (1, 2). T-B-NK+ phenotype can be
found in about 20% of SCID patients. This is an autosomal recessive condition that is
characterized by a complete absence of both circulating T and B lymphocytes, while
natural killer (NK) cells are at normal level and are functional (3). Such patients usually
die within the first year of life and stem cell transplantation is the only definite cure. The
phenotype is associated with a defect in the V(D)J recombination pathway and mutations
of several responsible genes have been identified. For example, mutations in either RAG
or LIG4 gene account for a subset of patients with T-B-NK+ SCID (4-7). Two groups of
T-B-NK+ with normal RAG and LIG4 genes have also been reported. Patients from one
of these groups have increased sensitivity to ionizing radiation of both bone marrow
cells and primary skin fibroblasts (RS-SCID) (8, 9). Another group of patients with a
similar SCID condition was found in Athabascan-speaking individuals of Navajo and
Apache descent (SCIDA) (10-12). Cells from RS-SCID and SCIDA patients showed
impairment in coding joint (CJ) formation in the extra-chromosomal V(D)J
recombination assay (13, 14). The gene defective in these two groups of SCIDs,
Artemis, was identified a few years later, and the impaired CJ formation in both RSSCID and SCIDA cells could be effectively complemented by Artemis constructs (15,
16). Thus, Artemis, a novel protein playing an essential role in V(D)J recombination and
NHEJ, is responsible for a subset of SCID.
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V(D)J recombination and Non-homologous end joining (NHEJ)

V(D)J recombination is a process that randomly rearranges the germline components
of the variable (V), diversity (D), and joining (J) gene segments of the T-cell receptor
(TCR) and Immunoglobulin (Ig). The completion of this process is indispensable for the
survival and maturation of T- and B- precursors, and it is responsible for the recognition
of diverse antigens by TCR and Ig (17, 18). Each V, D, and J segment is flanked by
recombination signal sequences (RSSs). The recombination is initiated by the lymphoidspecific recombinase activating proteins RAG1 and RAG2, which form a complex that
recognizes RSSs and introduces a DNA double strand break (DSBs) at the border of the
heptamer. There are two types of DNA ends generated during this process, one is called
the signal end and the other the coding end. The blunt signal end can be directly ligated
without further processing, while the covalently closed hairpin coding end requires
processing (including hairpin opening) before rejoining (19, 20). The rejoining of these
two types of ends are both mediated by the non-homologous end joining (NHEJ)
machinery, a pathway used to repair DSBs, and a signal joint (SJ) and a coding joint
(CJ) are generated, respectively. While the SJs are precise, CJs are much more diverse,
including variable nucleotide loss or addition (21). Deficiency in the V(D)J
recombination can result in failure of T- and B- lymphocytes maturation, and is
responsible for the SCID condition with a profoundly defective immune system.
In mammalian cells, DSBs can either be induced by different DNA-damaging agents
or stresses (for example, ionizing irradiation) or be a biological intermediate during the
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recombination of TCR and Ig genes. Unrepaired or misrepaired DSBs can lead to
cellular senescence, programmed cell death, gross chromosomal rearrangements, and the
development of different diseases, such as cancer. There are two mechanisms facilitating
DSBs repair, namely homologous recombination (HR) and non-homologous end joining
(NHEJ). And the NHEJ is the predominant DSB-repairing pathway in human cells (22,
23). The process of NHEJ can be described as 3 consecutive steps, end recognition,
termini trimming, and ligation. First, the Ku70/80 heterodimer recognizes and binds to
the DSB ends, forming a scaffold that holds the DNA ends together and recruits the
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) to the damaged sites
(24, 25). The damaged DNA ends activate DNA-PKcs, which is then able to
phosphorylate itself as well as other substrates. One of these substrates is Artemis. When
it is complexed with and activated by DNA-PKcs, Artemis acquires an endonucleolytic
activity that may be involved in the termini processing, as well as an ability to open
hairpins (26). Subsequently, the DNA ends are ligated by DNA Ligase IV and its
interacting protein XRCC4, which is also a phosphorylation substrate of DNA-PKcs
(27). Since it is an important pathway to maintain genomic integrity, deficiency in any of
the NHEJ components can lead to increased cellular sensitivity to DSB-inducing agents
and disrupted lymphocyte development.
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A

Figure A. Mechanism of V(D)J recombination. V(D)J recombination is initiated by
the lymphoid-specific recombinase activating proteins RAG1 and RAG2. RAG1 and
RAG2 form a multimeric complex that recognizes RSSs and introduces a DNA double
strand break (DSB) at the border of the heptamer. Two DNA ends are generated during
this process, a blunt and 5’ phosphorylated signal end which can be directly ligated, and
a covalently closed hairpin coding end, which requires processing (including hairpin
opening) before rejoining. The signal sequence and the coding sequence are both then
rejoined by a process involving the non-homologous end joining (NHEJ) machinery, a
pathway to repair DSBs, to generate a signal joint (SJ) and a coding joint (CJ)
respectively. (*Adapted from Yiyi Yan’s Master’s thesis)
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Artemis

Artemis is a member of the SNM1/PSO2 (Sensitive to Nitrogen Mustard) gene
family, which includes four other known mammalian homologs: SNM1, SNM1B,
CPSF73, and ELAC2 (28-31). Members of this family share a region of homology
termed the SNM1 domain, which contains a metallo-β-lactamase fold and a β-CASP
motif (metallo-β-lactamase-associated CPSF Artemis SNM1/PSO2) (32). This
conserved domain is on the amino terminal half of Artemis, spanning amino acids 1-385.
The metallo-β-lactamase fold was first described for the Bacillus cereus β-lactamase,
which is an enzyme that cleaves β-lactam ring, a structure common to many antibiotics.
This motif is adopted by various metallo-enzymes with diverse distribution and substrate
specificity, and its catalytic activity may be preserved in the SNM1 homologs. The βCASP motif appended to the metallo-β-lactamase fold has been shown to target the
SNM1 proteins to binding of nucleic acids and functions as a nuclease together with the
metallo-β-lactamase motif (reviewed in (33)) .
Artemis was originally identified molecularly as deficient in RS-SCID and SCIDA
cells, which are characterized by defects in V(D)J recombination. Later, a role of
Artemis in V(D)J recombination was verified by showing that Artemis possesses a 5’-3’
exonuclease activity on single-stranded DNA, and when activated by DNA-PKcs it gains
an endonuclease activity on 5’-3’ overhangs and the ability to open hairpins (26, 34-36).
This hairpin-opening ability is consistent with the defective coding joint formation
observed in Artemis-deficient cells. Since these cells also show a hypersensitivity to IR,
those findings suggested a role for Artemis in the NHEJ pathway of DSB repair. In fact,
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studies have showed that Artemis, as a substrate of ATM, is required for the repair of
approximately 10-15% of all DSBs caused by IR, and that the nuclease activity of
Artemis is necessary for the damage processing prior to NHEJ rejoining (37).
Artemis is a phosphor-protein that is extensively phosphorylated both in vitro and in
vivo by the three phosphatidylinositol 3-kinases (PIKs) ATM, ATR, and DNA-PKcs
depending on the type of DNA damage and cellular stress (37-46). At low to moderate
doses of IR (2-3 Gy), Artemis is phosphorylated by ATM. However, at a substantially
higher dose (10 Gy), DNA-PKcs also contributes to this modification (37, 39-42).
Interestingly, Artemis has also been shown to be phosphorylated by the ATR kinase in
vivo in response to other forms of stress such as UV irradiation, MMC, and hydroxyurea
(39, 41-43). Artemis is unlikely to have a direct role in repair of these lesions since
Artemis-deficient cells are not hypersensitive to UV or MMC (47). All these findings
indicate a wider role of Artemis in DNA damage response than just acting as a nuclease
in the NHEJ or V(D)J recombination.
Studies conducted by our lab and other groups have showed that Artemis plays
important roles in the cell cycle regulation in response to DNA damage. In Artemis
depleted humans cells, the initial imposition of the G2/M checkpoint after IR is normal,
however, the recovery from this checkpoint is defected, which is due to a delayed
activation of Cdk1-cyclin B complex. Mutation of two serine sites on Artemis, S516 and
S645, which are rapidly phosphorylated by ATM after IR, can prevent this activation,
indicating that the phosphorylation of Artemis is essential for cell cycle checkpoint
recovery after IR (41, 42).
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As mentioned above, ATR is responsible for the phosphorylation of Artemis after
UV and MMC. Damage induced by these agents can result in a block of DNA
replication fork progression, and therefore trigger an S-phase cell cycle checkpoint.
Artemis mutations on S516 and S645 cause a delayed recovery from this checkpoint due
to an impaired degradation of cyclin E. This is explained by the finding that the
phosphorylation of these two sites can enhance its binding to the SCFFbw7, which is the
ligase responsible for the ubiquitylation of Cyclin E (48).
As a multifunctional protein, Artemis can also act as a negative regulator of p53 in
response to oxidative stress produced by mitochondrial respiration in both primary cells
and cancer cell lines (49). p53 is phosphorylated, which is then stabilized and activated,
by DNA-PKcs upon such stress. Artemis can inhibit this phosphorylation and
stabilization, and therefore control the degree of activation of p53 in response to
oxidative stress.
Cells from Artemis-deficient SCID patients exhibit an impaired V(D)J
recombination as well as hypersensitivity to IR. Disruption of Artemis in mice leads to a
phenotype that is very similar to the human syndrome (47). In addition, Artemis null
mouse embryonic fibroblasts (MEFs) show an increased chromosomal abnormality
suggesting a role of Artemis in maintenance of genomic stability. While Artemis null
mice do not show increased tumorigenesis, Artemis/p53 double knockout mice develop
progenitor B lymphomas, indicating its potential function as a tumor suppressor (50).
All these recent findings suggest that Artemis is a multifunctional protein with
important roles in regulating different biological pathways. And some of these functions
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cannot be simply explained by its nuclease activity. However, the exact and detailed
mechanisms of how Artemis is involved in these regulations are yet to be elucidated.
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B

Figure B. Schematic of Artemis showing conserved SNM1 domain and (S/T)Q cluster on the C-termini.
10

Nucleotide Excision Repair (NER) and Xeroderma Pigmentosum (XP)

DNA damaging agents from the environment such as ultraviolet (UV) irradiation
constantly attacks mammalian DNA. The major lesions caused by UV light are
cyclobutane primidine dimers (CPD) and 6-4 photoproducts (6-4 PPs). These helixdistorting lesions, as well as bulky chemical adducts produced by psoralenes and
cisplatin, can be eliminated from the genomic DNA by a repair pathway known as NER
(51). NER is composed of two sub-pathways: global genome repair (GGR), which
repairs lesions over the entire genome, and transcription-coupled repair (TCR), which
removes damage in the template strand of transcriptionally active DNA. Approximately
30 genes are known to be involved in the NER pathway, and execute this multi-step
repair process in a sequential order: damage recognition (XPC, XPE, RNAPII),
unwinding of the helix (TFIIH), validation and stabilization of damage (XPA/RPA),
incision of the damaged DNA strand on both sides of the lesion (XPG and
XPF/ERCC1), excision of a 22-31-mer oligonucleotide containing the damage, and
DNA synthesis followed by strand ligation (DNA polymerase and DNA Ligase I)
(reviewed in (52)).
NER is important for cells to withstand potentially lethal and mutagenic DNA
damage, and to maintain the integrity of the human genome. A defective NER pathway
can result in heritable diseases known as Xeroderma Pigmentosum (XP) and Cockayne
Syndrome (CS) (53).
XP is a rare autosomal recessive disease that is characterized by hypersensitivity to
UV light. Patients with XP have pigmentation changes in the sun-exposed skin area and
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an increased incidence (1000-fold) of all types of skin cancer (basal cell carcinoma,
squamous cell carcinoma and melanoma) (53-55). XP has been classified into seven
complementation groups (XPA-XPG) by cell fusion analysis (53). The corresponding
genes of these groups are all involved in the NER pathway. Among these seven groups,
patients with XP-E disease have the mildest degree of clinical phenotype. Compared to
the defects in both GGR and TCR found in XP-A, -B, -D, -F, and -G patients, cells from
XP-E patients are only defective in the GGR sub-pathway of NER, which is caused by
the mutations of the damaged-DNA binding (DDB) gene (56).
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C

Figure C. Mechanism of Nucleotide Excision Repair. NER is a multi-step process.
Approximately 30 proteins sequentially execute damage recognition, unwinding the
helix, validation and stablization, incision, and DNA synthesis. (*Adapted from Yiyi Yan’s
Master’s thesis)
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Damaged-DNA Binding (DDB) Protein

DDB was first identified by testing the UV-induced damaged-DNA binding activity
of the cells from XP-E patients. DDB was purified as a heterodimer containing two
subunits, DDB1 and DDB2, and both of them are required for its damaged-DNA binding
activity (57, 58).
DDB1 is strongly conserved during evolution (59, 60). It localized in both the
cytoplasm and nucleus and binds tightly to damaged-DNA on chromatin upon UV in a
complex with DDB2 (61-63). Deletion of Ddb1 in fission yeast results in increased
spontaneous mutation rates as well as an impaired degradation of Spd1, a replication
inhibitor. The latter leads to a failed progression into meiosis (64, 65). Loss of Ddb1 in
fruit flies induces melanotic tumors and causes complete lethality, suggesting a critical
role of Ddb1 in development (66). Consistent with these results, a null mutation of Ddb1
has been found to cause early embryonic lethality in mice (67).
DDB2 homologs are only found in mammals. While no mutations of DDB1 have
been found in mammalian cells, several DDB2 mutations have been reported in XP-E
patient cells, which proved to be the cause of XP-E (68, 69). The transcription of DDB2
can be regulated by p53, E2F1, and BRAC1 (70-73). Interestingly, DDB2 protein is
rapidly ubiquitylated and degraded after UV, and the removal of DDB2 upon damage is
thought to be necessary for the later recruitment of other repair factors such as XPC (74,
75). Compared to Ddb1 null mice, depletion of Ddb2 is not embryonic lethal. Instead,
these animals exhibit an increased skin carcinogenesis (while enhanced Ddb2 expression

14

made them more resistant to UV-induced skin cancer) and decreased apoptosis after UVirradiation, in line with the phenotype observed in XP-E patients (76-78).
As implied by its name, DDB has an important function in UV-induced DNA
damage repair. While it has a higher affinity to 6-4PPs compared to CPD, DDB function
is mainly connected with the efficient GGR of CPD rather 6-4PPs. Recently, the
damage-bound (either 6-4PPs or an abasic site) structure of DDB1-DDB2 complex has
been described (79). DDB1 contains three WD40 seven-bladed β-propeller domains
designated BPA, BPB, and BPC in the order from N- to C- terminus, respectively.
DDB2 also has a β-propeller (BP) domain. In addition to that, DDB2 contains a helixloop-helix (HLH) segment on its N-termini. The BPA and BPC domain on DDB1 tightly
bind with each other, and this cluster interacts with the HLH segment on DDB2. On the
other hand, the BPB domain of DDB1 binds to the N-termini of Cul4A (80). The
interaction between damaged-DNA and the complex is mediated by the BP domain on
DDB2. This finding is consistent with the observation that mutations in DDB2
compromise the damaged-DNA binding activity.
Accumulated results have shown that the DDB complex is essential for the GGR and
functions at the very first step, damage recognition. Actually, it is now thought to be the
first factor that detects and binds to the damaged site in GGR. It seems to be required for
the accumulation of XPC and the recruitment of other NER factors onto the sub-nuclear
DNA damaged site, which may depend on an interaction between DDB and XPC (75,
81-83).
As mentioned above, genetic analyses of DDB1 disruptions have been performed in
different species, and results revealed broad functions for DDB1 beyond DNA repair.
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Lately, a new function of DDB complex in the protein ubiquitylation pathway has been
established. When ectopically expressed in cells, DDB can be purified as a part of
Cul4A-Roc1 E3 ligase complex, and several substrates of the Cul4A-DDB-Roc1
complex have been reported, which suggests a new function of DDB in regulating cell
cycle progression and DNA damage response through this new role (84). (This detail
will be described in the following section).

The Ubiquitin/Proteasome Pathway of Protein Degradation and Cul4A-Based
Complex

Protein degradation can be mediated by two different systems named lysosome and
ubiquitin-proteasome system (UPS), respectively. While the former mainly degrades
extracelluar proteins by digestive enzymes, the latter plays an important role in
degradation of cellular regulatory proteins. The UPS pathway is utilized to modulate a
wide range of diverse protein functions and cellular processes, and its deregulation has
been reported in various cancer cells. The ubiquitin-proteasome mediated degradation
pathway comprises two steps: the covalent attachment of ubiquitin to the substrate,
known as ubiquitylation, and the degradation of the substrate by the 26S proteasome
(reviewed in (85, 86)). Ubiquitin, a 76 amino acid highly conserved polypeptide, is
attached to substrate proteins through three sequential steps in the presence of ATP.
First, it is activated by E1 (activating) enzyme, and then is transferred to an E2 ubiquitinconjugating enzyme. Finally, an E3 ubiquitin ligase recognizes a specific target protein
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and promotes the ligation of ubiquitin to the substrate. Specificity of ubiquitylation for a
huge variety of cellular targets is achieved by the presence of a large pool of E3
ubiquitin ligases. In fact, there are more than 1000 distinct E3 ligases in higher
eukaryotes, which can be categorized into four major classes based of their specific
structural motif: HECT-type, RING-type, U-box type and PHD-finger type.
Cullin-RING E3 ligase (CRL) family, a subgroup of RING-type ligases, which
recruit E2s via a RING domain motif, is one of the largest classes of E3s (reviewed in
(87, 88)). There are 6 cullin family members (Cul1, 2, 3, 4A, 4B, and 5) in humans,
which are the scaffolds responsible for the assembling of the CRL (89). A small
ubiqutin-like protein Nedd8 can modify all of the cullins. The E3-ligase activity of
Cullin-based RING complexes is up-regulated when Nedd8 is covalently bound to the
cullin protein (90). A distinct character of CRLs is that Cullins do not directly bind to the
substrates, but rather recruit the substrates by a receptor and /or an adaptor protein. One
example of the well-characterized CRLs is the prototypical Skp1-Cul1-F box protein
(SCF) complex (91, 92). It is involved in the degradation of many cell cycle regulators
such as p27. The SCF complex consists of three invariable components: Roc1 (RINGfinger protein), which binds to E2s, Cul1 (Cullin1), providing a platform for complex
assembly, and Skp1, acting as an adaptor. Additionally, there is one variable component,
an F-box protein, which binds to Skp1 via its F-box and is responsible for substrate
recognition. For example, the F-box protein Skp2 binds to Skp1. In conjugation with
Skp2, the SCF complex (termed as SCFskp2) targets p27 for degradation(93, 94). In
addition to p27, p21, E2F1 and p57 have also been reported as targets of SCFskp2 (95-
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97). Increased Skp2 expression level, which is inversely correlated with p27, has been
detected in many human cancers, indicating the oncogenic function of Skp2.
Currently, another group of CRLs, known as DDB1-Cul4A-Roc1 complex, has been
undergoing extensive investigation. Cul4A is amplified and overexpressed in breast
cancer and hepatocellular carcinomas (98, 99). The association between Cul4A, DDB1
and Roc1 was first identified during immune-purification of ectopical DDB2 and
recently the crystal structure of this complex was resolved (80, 84). The globular Cterminal domain of Cul4A binds to Roc1, and the N-terminal arc-shaped domain of
Cul4A binds to the BPB domain on DDB1. This BPB domain is flexible, which allows a
rotation and tilt in a certain degree, thus providing space for the catalytic center of the
E2-Roc1 to move around. This observation is consistent with DDB1’s function in this
complex as an adaptor for various substrates.
Similar to the SCF complex, which utilizes a F-box protein to recruit a specific
substrate, the DDB1-Cul4A-Roc1 complex employs the interaction between DDB1 and
a group of substrate-recognizing receptor proteins to target different substrates. More
than 50 different DDB1-binding receptor proteins, one of which is DDB2, have been
identified. They are referred to as DCAFs (DDB1-Cul4A-associated factors), and
contain WD40 repeats, a protein motif that is responsible for protein-protein interaction
(100-103). DCAFs share a common motif defined as WDXR that is characterized by an
Arginine residue at position 16 following the WD dipeptide. This Arg residue is
essential, and its point mutation in some of the DCAFs can abolish their interaction with
DDB1. Interestingly, such a mutation in DDB2 can be found in several XP-E patient cell
lines (102).
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Recent studies have shown that the Cul4A-DDB1 ligase is responsible for the
degradation of more than twenty proteins that have diverse functions in DNA repair, cell
cycle regulation, and cellular DNA damage responses. For example, in association with
the adaptor protein CDT2, Cul4A-DDB1-CDT2 complex (Cul4A-DDB1CDT2) can target
Cdt1 for degradation during the cell cycle and in response to DNA damage (102, 104,
105). Cdt1 is a DNA replication licensing factor, and the interaction between Cdt1 and
PCNA is essential for its Cul4A-mediated degradation. The Cul4A-DDB1CDT2 can also
promote the degradation of p21 after UV-irradiation, which abolishes its inhibitory
effect on PCNA and therefore facilitates NER (106-108). Another ligase complex,
Cul4A-DDB1DDB2, promotes the polyubiquitylation on DDB2 and XPC (74, 75). While
this modification on DDB2 targets itself for degradation rapidly after UV,
polyubiquitylated XPC is stable and able to bind damaged DNA. These observations
support the model that DDB2 is removed from the lesion after binding to the damaged
site and promoting the XPC ubiquitylation, which is critical for the recruitment of XPC
and other repair factors. Cul4A-DDB1DDB2 also catalyzes the monoubiquitylation of
Histone H2A, H3 and H4, suggesting a role of Cul4A-DDB1 complex in regulating
chromatin remodeling upon DNA damage (109, 110). In association with CSA (Cul4ADDB1CSA), this E3 complex can target CSB for ubiquitylation (111). Both CSA and
CSB are involved in the TCR-NER, and the mutation of CSA is the cause of Cockayne
Syndrome (112). Several recent studies provided evidence showing that Cul4A-DDB1
complex is also responsible for the ubiquitylation and degradation of the cell cycle
inhibitor p27 (113, 114). The identification of its multiple substrates reveals the diverse
role of Cul4A-DDB1 complex plays in various cellular processes.
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In addition to Cul4A, DDB1 can also bind to Cul4B, a Cul4A-related Cullin found
only in mammals, and which shares significant sequence homology with Cul4A (101).
Although The Cul4B-DDB1 complex is less well understood, it has been shown that this
complex also has E3 ligase activity (115).
Genetic analyses of Cul4A deletion have been performed in different species. cul4a
deletion leads to a growth retardation in yeast as well as an impaired development in C.
elegans and Arabidopsis, consistent with its multiple functions in cells (116-118). In
mice, the phenotype of Cul4a differs from early embryonic lethal to mild or no apparent
phenotype, depending on the exact exon(s) being deleted in the experiment, and the
protein levels of its substrate such as DDB2, p27 are deregulated in the MEFs (119-121).
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D

Figure D. Schematic of SCFSkp2 complex (left) and Cul4-DDB1 complex (right).
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p27 kip

p27kip (hereafter p27) is a member of the kip family of cyclin-dependent kinase
(Cdk) inhibitors. Loss of a single allele of p27 confers increased susceptibility to
carcinogen-induced tumors in mice and low levels of p27 protein have been associated
with poor prognosis in several human cancers. p27 expression level peaks in quiescent
cells and drops upon mitogen stimulation (122, 123). It has a crucial role in the G1-S
transition by interacting with and inhibiting cyclin E-CDK2 activity (124). In early G1,
p27 increases cyclin D-CDK4/6 stability through promoting the complex assembly and
nuclear import (125). The cyclin D bound p27 serves as a reservoir for p27 and release
of p27 allows it to inhibit cyclin E /CDK2 complex through association with CDK2, thus
arresting the cell cycle at the G1 phase (126, 127).
p27 is regulated predominantly at the post-translational level through the
proteasome-mediated degradation pathway. However it is also regulated at the level of
transcription and sub-cellular localization. Transcription of p27 is induced by FOXO
family of forkhead transcription factors. Negative regulation of p27 promoter is
accomplished by Akt mediated inhibition of the FOXO transcription factor (128).
p27 function is also governed by its subcellular localization since to act as cell cycle
inhibitor it must be localized in the nucleus. This localization of p27kip is tightly
regulated by its phosphorylation. For example, Akt phosphorylates p27kip at Thr 157 and
Thr 198, which impairs the nuclear import of p27 (129, 130). Additionally, hKIS/MAPK
phosphorylates p27 at Ser10 (131, 132). This phosphorylation is necessary for p27kip
binding to CRM1 (a nuclear export carrier protein) and JAB-1 (Jun activation-domain
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binding, also known as CSN5), which allows its nuclear export. The cytoplasmic
localization of p27 serves two purposes. First, it favors cell cycle progression and may
facilitate cellular transformation. Secondly, it facilitates p27 a target for the E3-ubiquitin
ligase complex (133-135).
Several E3 ligase complexes responsible for p27 ubiquitylation and degradation have
been identified. SCFskp2 is the most well understood one, it is responsible for the
degradation of p27 in the nucleus during S-G2 phase. Skp2 is the substrate binding
protein in the SCF complex; it binds to p27 and promotes its ubiquitylation and
degradation within the nucleus only when p27 is phosphorylated at Thr187 by
CyclinE/Cdk2 complex (136-138). In addition to SCFskp2, KPC (Kip1 ubiquitinationPromoting Complex) has been reported to mediate ubiquitylation of p27kip. It targets
p27kip in the cytoplasm, in G1 phase, allowing its cytoplasmic destruction following
nuclear export (139). Recently, several groups reported that DDB1-Cul4A is also
responsible for the ubiquitylation of p27. A physical association between DDB1, Cul4A
and Skp2 has been shown. Furthermore, overexpression of DDB1 or Cul4A can promote
p27 proteolysis, indicating a role of DDB1-Cul4A in p27 ubiquitylation (113, 114, 140).
However, the regulation of this process is yet to be established.
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Chapter II. Materials And Methods

24

Cell Culture

HeLa, HEK293, HEK293T cells were grown in Dulbecco’s modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). hTert-RPE1 (hereafter
RPE1) cells were cultured in DMEM-F12 containing 10%FBS. Artemis mice were
provided by Frederick Alt. Preparation of MEF cells and genotyping was carried out as
described (47). Artemis +/+ and -/- MEFs were grown in DMEM containing 10%FBS,
1x nonessential amino acids, and 55mM 2-mercaptoethanol.

Inhibition of Protein Expression by siRNA

Small interfering RNA oligonucleotides (siRNAs) were synthesized with 3' dTdT
overhangs by Dharmacon (Lafayette, CO) in a purified and annealed duplex form. The
sequence of Artemis siRNA was 5’-UUAGGAGUCCAGGUUCAUG; The sequence of
the DDB2-1 siRNA was 5’-CCAGAAGACCUCCGAGA; and the sequence of DDB1
siRNA was 5’-GCAGAAUCGACUCAAUAAA. The following commercially available
siRNAs from Sigma were used: DDB2-2 (00101645) and p27 (00113637). siRNAs for
Cul4A (sc-44355) and Skp2 (sc-36499) were purchased from Santa Cruz Biotechnology.
SiRNAs were transfected into proliferating cells using oligofectamine RNA transfection
reagent (Invitrogen) in accordance with the manufacturer’s instructions. Three hundred
and eighty µl Opti-MEM was incubated with 8 µl oligofectamine for 5 minutes and then
20 µl (20 µM) siRNA was added to the mixture and incubated for another 20 minutes at
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room temperature. Medium was removed from cells cultured on a 60-mm plate at 3040% confluency, and the entire mixture together with 1.6 ml Opti-MEM was added to
the plates. Cells were cultured for 4 hours before 2 ml DMEM with 20% FBS was
added. Transfected cells were grown for 36-48 hours, after which cells were harvested.
In some cases, siRNAs were transfected by electroporation (Nucleofector Amaxa
GmbH, Cologne, Germany) according to the manufacturer’s instruction. siRNA at 1.5
µg was used for each 1-5 x 106 cells. Cells were harvested 36 hours after transfection.
Knockdown efficiency was determined by immunoblotting.

DNA constructs and DNA Transfection

A construct that expresses myc-tagged mouse Cul4A was obtained from Dr. Pengbo
Zhou (141). A plasmid containing the hDDB2 cDNA was a gift from Yoshihiro
Nakatani (84). The DDB2 open reading frame was removed by restriction enzyme
digestion and religated into the pENTR3C vector for use in the Gateway system
(Invitrogen). Human DDB1, Skp2 and Cul1 full-length cDNAs in pCMVSPORT6
vector were purchased from Open Biosystems. The cDNAs were amplified by PCR and
were ligated into the pENTR11 vector. Human Artemis cDNAs and Artemis
phosphorylation mutants were prepared as previously described (41, 42). Artemis
deletion constructs were generated using restriction enzyme digestion on pENTR11Artemis plasmid. DNAs in the pENTR11 vectors were transferred via site-specific
recombination (LR reaction, Invitrogen) to various destination vectors with a CMV or
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T7 promoter for either in vivo or in vitro expression. The Flag-p27 was provided by Dr.
Mong-Hong Lee (M.D. Anderson Cancer Center), and Flag-p27 T157A, T157D, T187A
and T187D were generated by PCR-based mutangenesis (Stratagene). All plasmid
constructs were confirmed by DNA sequencing. A construct that expresses GST-tagged
human Cdt2 was obtained from Dr. Jianpin Jin (University of Texas Medical School at
Houston).
Both transient and stable DNA transfections were performed using FuGENE6
transfection reagent (Roche Molecular Biochemicals) according to the manufacturer’s
recommendations Selective medium for stable transfections with the plasmids derived
from pDEST27 contained G418 at a concentration of 400 µg/ml (Sigma).

Immunoblotting

Whole-cell extracts were prepared as follows. Cells were grown in monolayer
culture in DMEM with 10% FBS to 80% confluency. Medium was removed and 2X
SDS loading buffer was added to the dish to lyse the cells. After the proteins were
denatured at 100oC for 3 minutes, the sample was passed through a 27 1/2 gauge needle
for several times. Protein samples were separated by SDS polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to a nitrocellulose membrane
(Millipore), and the membrane was blocked with 5% dry milk in 1X phosphate-buffer
saline (PBS). Immunoblotting was performed using standard protocols with antibodies
diluted in binding solutions (5% BSA in 1X PBS with 0.05% sodium azide, or 5% dry
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milk in 1X PBS with 0.1% Tween-20). Protein detection was performed using the
enhanced chemiluminescent assay (Amersham Pharmacia Biotech). Secondary
antibodies conjugated with horseradish peroxidase specific for mice, rabbit or goat IgG
were obtained form Amersham-Pharmacia or Santa-Cruz Biotechnology.

Antibodies

Artemis polyclonal antibodies and Artemis phosphor-specific antibodies were
generated as previously described. The following commercially available antibodies
were used: goat anti-DDB1 (abCAM), rabbit anti-DDB2, mouse and rabbit anti-GFP,
rabbit anti-Skp2, rabbit anti-p27 (Santa Cruz Biotechnology), monoclonal antibody for
bromodeoxyuridine (BrdU) (Becton Dickinson), mouse anti-HA (Roche), mouse antiFlag (Sigma), mouse anti-MBP (New England Biolab), and mouse anti-GST (Cell
Signaling). Rabbit anti-Cul4A, anti-DDB1 and anti-Cdt1 antibody was kindly provided
by Dr. Yue Xiong (University of North Carolina).

Protein Expression and In Vitro Translation

The in vitro protein translation was performed as previously described in my master
thesis (142). In Brief, Artemis, DDB1, DDB2 and Cul4A cDNAs were cloned into
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pDEST vectors under the T7 promoter. Proteins labeled with 35S-methionine were
produced in vitro using the T7 TNT Coupled Reticulocyte Lysate System (Promega).
Bacterially expressed glutathione S-transferase (GST)-Artemis (full length and
truncated), MBP-DDB2, MBP-Cul1, MBP-Skp2 were purified using GST beads
(Amersham) or amylose resin (New England Biolabs), respectively, according to the
manufacturer’s protocols.

Immunoprecipitation, GST Pull-down and Mass Spectrometric Analyses

Co-immunoprecipitation (co-IP) experiments were performed as previously
described (42). In brief, cells were lysed with EBC buffer (50mM Tris pH 8.0, 120mM
NaCl and 0.5% Nonidet P-40). Indicated antibodies were incubated with the cell lysates
before the protein A-Sepharose CL-4B (Amersham Pharmacia biotech) were added.
For in vitro IP experiments, 35S-methionine-labeled proteins were mixed and were
incubated on ice for 1 hour. Two hundred ml 1X PBS together with the indicated
antibody was added, and the reactions were incubated at 4oC for 1 hour. Ten ml of
protein A-Sepharose CL-4B beads were added, and the reactions were rotated for
another hour at 4oC. After the supernatants were removed, beads were washed. Bound
proteins were eluted by 2X SDS sample loading buffer and separated on SDS-PAGE for
autoradiography.
The in vitro GST pull-down assay was performed as previously described in my
master thesis. Briefly, purified proteins were mixed and incubated at 4oC overnight in
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the presence of BSA and then GST beads were added to the mixture. After a 1-hour
incubation, beads were washed, and bound proteins were eluted with 2X SDS loading
buffer and separated by SDS-PAGE.
The purification of Artemis complexes for mass spectrometric analysis was
previously described in my master thesis. HEK293 cells were transfected with a GSTtagged Artemis expressing plasmid. Fifty x 106 transfected or control cells were lysed
with Net-N buffer and the lysates were incubated with GST beads. Immunocomplexes
were resolved by SDS-PAGE, stained with Coomassie blue, and protein bands were
digested with trypsin and subjected to mass spectrometric analysis for identification
(M.D. Anderson Cancer Center proteomics core facility).

In Vivo Ubiquitylation Assay

HeLa cells were transfected with HA-ubiquitin, GST-Artemis, and Flag-p27. Fortyeight hours after transfection, 20 µM MG-132 was added into the media. Cells were
harvested 5 hours after MG-132 treatment in lysis buffer (50 mM Tris PH 7.5, 0.5 mM
EDTA, 1% SDS and 1 mM DTT). Lysates were boiled for 10 minutes and then diluted
10 times in Net-N buffer containing protease inhibitors (Roche). Immunoprecipitations
were performed using anti-Flag M2-conjugated agarose (Sigma).

Serum Starvation and Cell Cycle Analyses
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For serum starvation experiments, RPE1 cells were grown in DMEM-F12 media
containing 10% FBS. Twenty-four hours after transfection with indicated DNA
constructs or siRNAs, media was removed and dishes were washed with 1XPBS twice.
Then DMEM-F12 with 0.1% FBS was added, 24 hours later (or at different time points
as indicated in the figure), cells were harvested and fixed in 75% ethanol, and DNA was
labeled by propidium iodide (PI) for flow cytometry analysis.
For BrdU labeling, cells were labeled with BrdU at a concentration of 10 µM for 30
min prior to harvesting and fixation. Cells were then incubated in PBS containing 4%
BSA and 0.2% Triton X-100 for 1 hour. After the DNA was denatured by 2N HCl for 30
minutes, cells were incubated with anti-BrdU antibody for 1 hour, and then fluorescein
isothiocyanate-conjugated goat antibodies to mouse IgG were added. After washing with
PBS, cells were resuspended in PBS with 50 µg/ml PI and 20 µg/ml DNase-free RNase.
Fluorescence was measured on FACS Calibur flow cytometer (BD Biosciences) using
488 nm laser excitation by the cytometry and cellular imaging core facility in M.D.
Anderson Cancer Center.

RNA Purification and RT-PCR

Total cellular RNA was extracted using the RNAqueous-4PCR kit (Ambion, TX).
One µg of RNA was reverse-transcribed into cDNA. The cDNA was subjected to real-
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time quantitative PCR using the SYBR green supermix and iCycler iQ Real-time PCR
detection system (Bio-Rad). All results were normalized to the amount of GAPDH.
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Chapter III. Results
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Artemis interacts with the DDB heterodimer via DDB2

It is known that Artemis is required for V(D)J recombination (15, 26), has a minor
role in the repair of DBSs (37), and is involved in cell cycle checkpoint regulation (41,
42, 48). However, the precise mechanism of how Artemis controls these biological
functions needs to be further elucidated. In order to investigate the function of Artemis,
we initiated a search for novel cellular proteins that interact with human Artemis. And
the following results presented in this section has been previously described in my
master thesis (142). In summary, a construct expressing GST-Artemis was transfected
into HEK293 cells, and proteins in cell lysates were pulled-down using glutathione
sepharose beads, and separated by SDS-PAGE. Coomassie blue staining of the resulting
gel is shown in Fig. 1A. A mock purification from non-transfected cells was performed
as a negative control. Polypeptides with the molecular mass of ∼ 125 KD were
specifically detected in the transfected cell population. This band was analyzed by mass
spectrometric analysis, and shown to contain GST-Artemis and DDB1, suggesting that
DDB1 might be an Artemis interacting protein.
To confirm this interaction, HEK293 cells were treated with UV, IR, or mock
treated, and 2 hours later co-IPs were carried out using Artemis-specific antiserum. As
shown (Fig. 1B), DDB1 and Artemis co-IPed with each other, suggesting that Artemis
interacts with DDB1 both before and after DNA damage. A reciprocal IP was also
performed using DDB1 antibody, and Artemis was detected in the precipitates both with
and without UV treatment (Fig. 1C). Because DDB1 can rapidly translocate from the
cytoplasm to the nucleus and tightly bind to chromatin after UV irradiation (61), we
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examined whether its interaction with Artemis would be affected by UV irradiation as a
function of time. HEK293 cells were UV irradiated and harvested at different time
points following treatment. Upon IP using anti-Artemis serum, we found that DDB1
interacted with Artemis with or without UV treatment, and the amount of DDB1
precipitated by Artemis specific serum was not affected in response to UV up to 2 hours
after irradiation (Fig. 1D). Taken together, these experiments demonstrate that Artemis
and DDB1 form a complex, and this interaction is not affected by the DNA damage
induced by UV or IR irradiation. These findings are also interesting from the standpoint
that Artemis is rapidly phosphorylated in response to DNA damage by PIKKs at
multiple sites (41), but this phosphorylation apparently does not affect its interaction
with DDB1.
DDB was originally purified as a DDB1-DDB2 heterodimer that tightly binds to
chromatin after UV-inflicted DNA damage. Since Artemis interacts with DDB1 in vivo,
I examined whether Artemis also interacts with DDB2. GST-DDB2 was expressed in
HEK293 cells, and the result of a co-IP experiment performed using Artemis anti-serum
indicated that Artemis interacts with DDB2 (Fig. 1E). Also, an interaction between
ectopically expressed GFP-Artemis and GST-DDB2 was observed in HEK293 cells
(Fig. 1F). From these results, I conclude that Artemis interacts with both DDB1 and
DDB2 in vivo, presumably as components of the DDB complex. In order to determine
which subunit of the DDB complex directly interacts with Artemis, I conducted the
following in vitro assays. 35S-methionine-labeled Artemis, DDB1, and GST-DDB2 were
translated in vitro using rabbit reticulocyte lysate, and subsequently mixed together for
co-IP assays. Although Artemis and DDB1 interact with each other in vivo, Artemis was
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not co-IPed by DDB1 antibody in vitro, nor was DDB1 co-IPed by Artemis antiserum
(Fig. 2A,B). However, GST-DDB2 was able to be co-IPed by Artemis antibody (Fig.
2C), indicating a direct interaction between Artemis and DDB2. This direct interaction
was confirmed by a GST-pull down assay using recombinant GST-Artemis and MBPDDB2 expressed and purified from E. coli (Fig. 2D). Taken together, these results
demonstrated a direct association between Artemis and DDB2, but not with DDB1,
indicating that DDB2 is the subunit that mediates the Artemis interaction with the DDB
complex.
To determine the region of Artemis that mediates the interaction with DDB, I
generated a number of Artemis deletion constructs, and examined their ability to interact
with DDB1 and DDB2. GST-tagged truncated and full-length Artemis constructs were
transfected into HEK293 cells, and GST pull-down assays were performed. As shown
(Fig. 3A,B), both DDB1 and DDB2 were pulled-down with full-length Artemis
consistent with the results shown above. Among the deletion mutants, only mutant B, in
which amino acids 71-292 were deleted, lost its ability to interact with DDB1 or DDB2
(Fig. 3C). This region is located within the conserved SNM1 domain, suggesting that an
intact conserved domain on Artemis is essential for its interaction with DDB complex.
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Figure1. Artemis interacts with DDB1 and DDB2 in vivo.

Figure 1A∗. Gel stained with Coomassie blue showing proteins from a GST-Artemis
pull-down experiment. GST-Artemis expressed in HEK293 cells was pulled-down by
glutathione sepharose beads (left lane). A pull-down from untransfected cells was used
as a control (middle lane). Labeled band indicates proteins identified by mass
spectrometric analysis.

Figure 1B∗. Immnuoblot showing that endogenous DDB1 interacts with Artemis in
vivo before and after UV or IR irradiation. HEK293 cells were treated with UV (25
J/m2), IR (10 Gy), or mock treated (UT). Cells were then harvested for co-IP analysis by
Artemis antiserum two hours post-irradiation.

Figure 1C. Reciprocal co-IP experiment showing that endogenous Artemis interacts
with DDB1 in vivo before and after UV damage. HEK293 cells were treated with UV
(25 J/m2) or left untreated. Cells were incubated for two hours after treatment, and then
harvested for analysis. IP was performed using rabbit polycolonal anti-DDB1 antibody.

Figure 1D∗. Artemis interacts with DDB1 after UV irradiation. HEK293 cells were
irradiated with UV (25 J/m2). After irradiation, cells were incubated for the indicated
time prior to harvesting. IP was carried out using Artemis-specific antiserum (Art) or
pre-immune serum (Pre) as control.
∗ indicates adapted from my master thesis.
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Figure 1E. Immunoblot showing that endogenous Artemis interacts with ectopically
expressed DDB2. HEK293 cells were transfected with GST-DDB2, and 48 hours later
cells were harvested for co-IP experiments using Artemis antiserum.

Figure 1F∗. Co-IP showing the interaction between Artemis and DDB2. GST-DDB2
and GFP-Artemis were co-transfected into HEK293 cells, and 48 hours later cells were
harvested for co-IP experiments using rabbit polyclonal antibody against GFP or rabbit
IgG for control.
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Figure 2. Artemis directly interacts with DDB2

Figure 2A∗, 2B∗. Artemis does not interact with DDB1 in vitro. Artemis and DDB1
labeled with 35S-methionine were expressed by in vitro transcription coupled translation.
Artemis and DDB1 were mixed and IPed with DDB1 antibody (Fig. 2A) or Artemis
antiserum (Fig. 2B) as indicated. Bound proteins were eluted, separated by SDS-PAGE,
and detected by autoradiography.

Figure 2C∗. Artemis directly interacts with GST-DDB2 in vitro. Artemis and GSTDDB2 were in vitro translated and labeled with 35S-methionine. Synthesized proteins
were mixed and incubated as indicated. The panels show the autoradiography of labeled
proteins. Immunoprecipitation was performed by Artemis serum or pre-immune serum.

Figure 2D∗. Purified recombinant Artemis and DDB2 directly interact with each
other. GST-Artemis, GST, and MBP-DDB2 proteins were expressed and purified from
E. coli. Purified proteins were mixed as indicated, and pull-down assays were performed
and analyzed by immunoblotting.

41

2B*

2A*

IP
DDB1

1/15 Input

IgG

Art

IP
Art

IgG

DDB1

DDB1

DDB1
Artemis

Artemis

2C*

IP
Art

IgG

1/15
Input

Artemis
GST-DDB2

2D*

GST pull-down
GST-Artemis
MBP-DDB2
GST

+
+

1/15 input
+

+
+

+
+

GST-Artemis
MBP-DDB2
GST

42

1/15 Input
Art

DDB1

Figure 3. DDB interacts within the conserved SNM1 domain of Artemis.

Figure 3A∗. Mapping of Artemis region that is required for interaction with DDB2.
GST-Artemis constructs and GST-GUS (negative control) were expressed in HEK293
cells, and fusion proteins were purified using GST beads. Beads with bound proteins
were incubated with bacterially expressed and purified MBP-DDB2. Beads were then
washed and bound proteins were subsequently eluted and separated by SDS-PAGE for
immunoblotting using GST or MBP antibody.

Figure 3B∗. The DDB2 interaction region on Artemis is also required for its
interaction with DDB1 in vivo. Indicated GST-Artemis constructs and GST-GUS were
expressed in HEK293 cells, and pull-down assays were performed using GST beads.
Bound proteins were analyzed by Western blot using DDB1 or GST antibody.

Figure 3C∗. Schematic showing interaction of DDB with Artemis deletion mutants
derived from data shown in A and B.
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siRNA mediated down-regulation of Artemis or DDB2 stabilizes p27

DDB1 and DDB2 are known components of Cul4A-based E3 ligase complexes (84).
Substrates of these complexes are involved in many important cellular pathways such as
cell cycle regulation and the DNA damage response. Because Artemis interacts with
both DDB1 and DDB2, I next investigated whether Artemis also plays a role in
regulating the stability of Cul4A-DDB1 substrates. DDB1-Cul4A has been shown to
promote the degradation of the Cdk inhibitor, p27 (114). However, the substrate receptor
remained unknown and neither DDB2 nor Artemis had been implicated in this
regulation. We depleted expression of Artemis or DDB2 in HeLa cells using specific
siRNAs, and examined p27 protein levels by immunoblot analysis (Fig. 4A, lanes 1-4
and 8-11). Interestingly, p27 levels were significantly increased in cells with decreased
Artemis or DDB2 expression compared to control cells treated with a non-specific
siRNA. This increase in p27 protein levels was reduced when an Artemis construct
resistant to the Artemis specific siRNA was expressed in the cells depleted of
endogenous Artemis (Fig. 4A, lane 5-7). Additionally, p27 levels were also found to be
lower in Artemis-/- mouse embryonic fibroblasts (MEFs) compared to wild-type MEFs
(Fig. 4B). Moreover, when Artemis or DDB2 was overexpressed in HeLa cells, the p27
level was significantly decreased (Fig. 4C).
p27 is regulated at both transcriptional and post-translational levels (143-146). Thus,
to rule out the possibility that p27 accumulation in the absence of Artemis or DDB2 was
a result of increased transcription, real-time PCR was performed in HeLa cells depleted
of Artemis or DDB2 by siRNA transfection. As shown (Fig. 4D), p27 mRNA levels
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remained stable in transfected cells with or without UV treatment, indicating that the
observed accumulation of p27 is regulated at a post-transcriptional level. In addition,
upon treatment with the protease inhibitor MG-132, the differential expression of p27
protein levels between control and Artemis or DDB2 overexpression was abolished (Fig.
4E). I conclude from these results that alterations in expression of Artemis or DDB2
affect the stability of p27 in the cell, and this due to the protein degradation mediated by
the ubiquitin-proteasome pathway.

Artemis and DDB2 promote the ubquitylation of p27 in vivo

So far, I have shown that Artemis and DDB interact with each other and regulate
p27’s stability. Next, I investigated the direct involvement of Artemis and DDB2 in
p27’s ubiquitylation.
As shown in Fig. 4F, overexpression of Artemis or DDB2 promotes the
ubiquitylation of p27 in the presence of MG132 (compare lanes 2 and 4, and lanes 2 and
5). These findings are consistent with the observation that overexpression of Artemis or
DDB2 reduces p27 protein level in vivo (Fig. 4C), and indicate that these two interacting
proteins plays a significant role in p27 ubiquitylation and hence degradation in vivo.
It has been shown that p27 can be phosphorylated at different sites, and this
modification is important for regulation of its stability, cellular localization and
biological function. For example, as a Cdk2 kinase substrate, p27 is phosphorylated at
Thr 187, which is required for SCFSkp2 mediated ubiquitylation. In addition, Akt can
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phosphorylate p27 at Thr 157 and this phosphorylation is responsible for its cytoplasmic
retention. To test if phosphorylations of these sites are required for Artemis mediated
p27 degradation, wild-type, T157A or T187A mutant p27 was overexpressed in HeLa
cells together with GST-Artemis or GST-GUS. Then, the Flag-p27 level was detected.
As shown in Figure 4G, both wild-type and mutant p27 were degraded when GSTArtemis was co-expressed in the cell. This is also supported by the following
experiment. I expressed wild-type or mutant p27 with or without overexpression of
Artemis and then the in vivo ubiquitylation assay was performed. As shown in Figure
4H, Artemis can promote the ubiquitylation of both wild-type and mutant p27 (compare
lane 1-3). This result suggests that Artemis can promote the degradation of p27 in the
nucleus and that p27’s phosphorylation by Cdk2/Cyc E is not required for this activity.
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Figure 4. Artemis and DDB2 regulate p27 protein levels via ubiquitin-mediated
pathway.

Figure 4A. p27 accumulates in Artemis or DDB2 depleted cells. HeLa cells were
transfected with control (NS), Artemis and/or DDB2 siRNAs. Forty-eight hours after
transfection, cells were harvested and cell lysates were subjected to immunoblot
analysis. Artemis-1 and Artemis-2, DDB2-1 and DDB2-2 indicate distinct siRNAs. In
lanes 5-7, 24 hours after siRNA transfection, cells were transfected with control plasmid
DNA (C) or an Artemis construct refractory to Artemis siRNA (R). Cells were then
incubated for an additional 24 hours before harvesting. GAPDH and Actin indicate
loading controls.

Figure 4B. p27 accumulates in Artemis null MEF cells. Lysates prepared from
Artemis+/+ and Artemis-/- MEF cells were subjected to immunoblot analysis for p27.

Figure 4C. Overexpression of Artemis or DDB2 reduces p27 levels. Hela cells were
transfected with GST-Artemis (left panel) or GST-DDB2 (right panel) plasmid DNAs or
treated with mock transfections. Forty-eight hours after transfection, cells were
harvested and cell lysates were subjected to immunoblot analysis.
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Figure 4D. p27 mRNA is stable in Artemis or DDB2 depleted cells. mRNA was
isolated from HeLa cells 48 hours after transfection with control (NS), Artemis or DDB2
siRNAs. Cells were exposed to UV or mock treated and incubated for 2 hours prior to
harvesting. p27 mRNA levels were determined by real-time PCR. Results were
normalized using GAPDH as an internal control.

Figure 4E. Artemis and DDB2 regulate p27 protein levels through proteosome
mediated degradation. HeLa cells were transfected with GST-Artemis or GST-DDB2
DNAs. After 48 hours cells were treated with 10 µM MG-132, and 5 hours later cells
were harvested and lysates subjected to immunoblot analysis.
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DDB2

Figure 4F. Artemis and DDB2 promote ubiquitylation of p27 in vivo. HeLa cells
were transfected with indicated amount of Flag-p27, HA-Ub, GST-Artemis, and GSTDDB2 DNAs. Cells were harvested 48 hours after transfection, and an in vivo
ubiquitination assay was performed using anti-Flag M2 agarose as described in materials
and methods. Ubiquitinated proteins were detected using an HA antibody. Flag-p27
indicates a loading control at 10% of input.

Figure 4G. Artemis promotes the degradation of p27 independent of its
phosphorylation on T187 or T157. Flag-tagged wild-type, T187A, or T157A p27 were
expressed in the HeLa cells together with either GST-Artemis or GST-GUS as indicated.
Cells were harvested 48 hours post-transefection. The amount of p27 protein was
determined by SDS-PAGE followed by immunoblot using monoclonal Flag antibody.

Figure 4H. Artemis promotes ubiquitylation of p27 independent of its
phosphorylation on T187 or T157. HeLa cells were transfected with Flag-tagged wildtype (lane 1 and 4), T187A (lane 2), or T157A (lane3) p27, HA-Ub, GST-Artemis
(lane1-3), and GST-GUS (lane 4). Forty-eight hours after transfection, an in vivo
ubiquitylation assay was carried out as indicated in Figure 4F.
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Artemis regulates p27 protein level through Cul4A-based E3 ligase complex

Artemis interacts with DDB1 and DDB2, which are both components of the Cul4Abased E3 ligase complex. Recently, this E3 complex has been shown to target p27 for its
degradation (114). Here, I showed that Artemis and DDB2 could promote p27’s
ubiquitylation. Based on this evidence, I hypothesized that Artemis might regulate p27’s
stability through a Cul4A-DDB1DDB2 mediated pathway. Several studies have shown
that overexpression of Cul4A or DDB1 promotes p27 degradation (113, 114, 140);
therefore, I examined the effect of Cul4A or DDB1 overexpression on p27 protein levels
in cells treated with Artemis or DDB2 siRNAs. As shown in Fig. 5A (lanes 1-5), when
cells were treated with control siRNA, transfection of Cul4A or DDB1 destabilized p27
as did transfection of GST-Artemis or GST-DDB2. However, p27 protein levels
remained largely unchanged when either Artemis of DDB2 specific siRNA was used to
treat these DNA transfected cells (Fig. 5A, lane 7, 8, 11, 12). In addition, GST-DDB2
did not promote p27’s degradation when it was overexpressed in Artemis depleted cells,
nor did GST-Artemis overexpression in the DDB2 depleted cells (Fig. 5A, lanes 9, 13),
suggesting that they are involved in a common pathway. Furthermore, in a reciprocal
experiment I depleted Cul4A and transfected GST-DDB2 or GST-Artemis DNA at the
same time. The overexpression of either Artemis or DDB2 did not cause reduction of
p27 protein levels in Cul4A depleted cells (Fig. 5B, lane 4-6)). Taken together, these
results suggest that acting together, Artemis and DDB2 are both required for Cul4Amediated p27 degradation pathway.
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It has been reported that the Cul4A-DDB1 complex may utilize the F-box protein
Skp2, which normally associates with SCFSkp1, as a substrate receptor to target p27 for
ubiquitylation (114). Therefore, I examined whether Skp2 was also required for Artemis
or DDB2 promoted p27 degradation. As shown (Fig. 5B, lanes 7-9), when cells were
depleted of Skp2, overexpression of Artemis or DDB2 did not destabilize p27, indicating
that Skp2 may also be involved in the Artemis-DDB2 mediated p27 degradation
pathway. In the cells treated with the Skp2 siRNA, we observed a more dramatic
stabilization of p27. This is consistent with the proposed possibility that Skp2 can be
utilized by two p27 targeting E3 ligase complexes, namely SCFSkp2 and Cul4A-DDB1.
The activity of Cullin-based E3 ligase activity can be regulated by a small ubiquitin
like molecule, Nedd8. The attachment of Nedd8 to the Cullins leads to an increased
ligase activity. Next, I examined if Artemis or DDB2 can change the neddylation level
of Cul4A and hence the p27 degradation. As shown in Figure 5C, depletion of Artemis
or DDB2 did not affect the level of neddylation of Cul4A (indicated by the upper band
detected by Cul4A antibody). Additionally, unlike overexpression of DDB1, which can
increase Cul4A neddylation (114), its level remained unchanged in cells transfected with
Artemis or DDB2 constructs (data not shown), indicating that Artemis and DDB2 do not
regulate Cul4A-DDB1 complex through the neddylation modification.
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Figure 5. Artemis and DDB2 regulate p27 protein levels through a Cul4A-based E3
ligase complex.

Figure 5A. Artemis and DDB2 are required for p27 degradation by the Cul4A-based
E3 ligase complex. Hela cells were transfected with control, Artemis or DDB2 siRNAs.
After 24 hours, cells were transfected with the indicated DNA, and 24 hours later cells
were harvested for immunoblot analysis.

Figure 5B. Cul4A is required for Artemis or DDB2-mediated p27 degradation. HeLa
cells were transfected with control, Cul4A or Skp2 siRNAs, and 24 hours later, cells
were transfected with the indicated DNA. Cells were harvested after an additional 24
hours for immunoblot analysis.

Figure 5C. Cul4A neddylation is not regulated by Artemis depletion. HeLa cells
were transfected with control, Artemis and Cul4A siRNA as indicated. Forty-eight hours
after transfection, cells were harvested and the indicated proteins were detected by
immunoblot analysis. The upper band detected in the Cul4A row is the nedd8-modified
form of Cul4A.
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Artemis interacts with Cul4A, p27, Skp2 and Cul1

My results demonstrate an interaction between Artemis and the DDB complex, and
that Artemis is involved in the Cul4A-DDB1-mediated degradation of p27. Since DDB1
was shown to be associated with Cul4A and control the degradation of p27, I examined
whether Cul4A and p27 are also Artemis interacting partners. Immunoprecipitation
experiments performed in Figure 6A shows that Cul4A and p27 specific antibodies can
both pull down endogenous Artemis, indicating an association between Artemis and
these proteins in vivo. Next, a direct interaction between purified GST-Artemis and
MBP-p27 proteins was confirmed by the in vitro GST-pull down assays (Fig. 6B). In the
previous section, I have shown that Skp2 is also involved in the Artemis-mediated p27
degradation. To understand the function of Skp2 in the Artemis-dependent pathway, we
examined the physical interaction between Artemis and Skp2. As shown in Figure 6C,
Artemis directly associates with Skp2 in vitro. The F-box protein Skp2 acts as a receptor
recruiting p27 in the SCFSkp2 complex, and it also has a role in Cul4A-DDB1 mediated
p27 degradation. As a component of Cul4A-DDB1 complex, Artemis not only interacts
with p27, but also directly interacts with Skp2 and DDB2, both of which are substratespecific receptors for Cullin-based ligase. These results suggest that Artemis is
functioning in substrate recruitment in the Cul4A-DDB1 ligase complex.
The published work by our lab has shown that Artemis can regulate the stability of
Cyclin E through its interaction with Fbw7, another F-box protein utilized by SCF
complex. Therefore, I next investigated the possibility that Artemis may interact with
Cul1. GST-Artemis and MBP-Cul1 were expressed in E. Coli, and a direct interaction
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was observed in the in vitro assay as shown in Figure 6B. This result indicates that the
function of Artemis in the E3 ligase complex is not limited to the Cul4A-DDB1
complex, but in the Cul1-based ligase as well.
About two dozens of substrates have been identified for the Cul4A-DDB1 ligase
complex (147, 148). Here I showed an involvement of Artemis in this complex to
promote the ubiquitylation of p27. To determine if this role of Artemis is substrate
specific, I examined the protein level of Cdt1, a known substrate of the Cul4A-DDB1Cdt2
complex (104), in Artemis depleted cells. It has been shown that Cdt1 can be degraded
by Cul4A-DDB1Cdt2 both during S phase and after UV irradiation. As indicated in Figure
6D, Cdt1 levels in cells with and without UV treatment were not affected by Artemis
knockdown. Moreover, no interaction between Artemis and Cdt2, the receptor protein
for Cdt1 in the Cul4A-DDB1 complex, was detected. Taken together, these results
suggest that Artemis is specifically involved in the degradation of certain substrates such
as p27 as opposed to playing a general role in Cul4A-DDB1-mediated substrates
ubiquitylation.
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Figure 6. Artemis interacts with Cul4A, p27, Skp2 and Cul1.

Figure 6A. Artemis interacts with Cul4A and p27 in vivo. Immunoblot analysis
showing co-IP experiments performed in HEK293 cells using the indicated antibodies.

Figure 6B, C. Artemis directly interacts with p27, Skp2 and Cul1 in vitro. GST,
GST-Artemis, MBP, MBP-p27, MBP-Skp2, and MCP-Cul1 were expressed in E. Coli.
Purified proteins (as indicated) were mixed and subjected to in vitro GST pull-down
assays. Anti-GST and anti-MBP antibodies were used for immunoblotting.
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Figure 6D. Artemis is not a regulator of the Cul4A-DDB1 substrate Cdt1. Upper
panel: UV-induced Cdt1 is not affected by Artemis depletion. HeLa cells were
transfected with control (NS) or Artemis siRNAs, and 48 hours later cells were treated
with or without 20 J/m2. After a 2-hour incubation cells were harvested for immunoblot
analysis. Actin is shown as a loading control. Lower panel: Artemis does not interact
with Cdt2. The indicated constructs were transfected into HeLa cells, and 48 hours later
cells were harvested for GST pull-down and GFP co-IP assays. Anti-GFP and anti-GST
antibodies were used to detect the indicated proteins.
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Artemis and DDB2 regulate cell cycle progression

p27 is a well known cell cycle inhibitor. It has a crucial role in the G1-S transition by
interacting with and inhibiting cyclin E-CDK2 complex. Here I showed that the stability
of p27 is regulated by Artemis and DDB2 through Cul4A-DDB1 E3 ligase complex.
These results led me to investigate the possibility that Artemis and DDB2 are involved
in controlling cell cycle progression through p27. Htert-RPE1 cells, a telomeraseimmortalized primary human cell line, were employed for cell cycle analysis. First, I
depleted the expression of Artemis and/or p27 by specific siRNAs. Cells treated with
p27 siRNA exhibited a higher level of BrdU incorporation, indicating a less inhibited
G1/S transition, while Artemis depleted cells demonstrated a smaller S phase population.
However, when Artemis and p27 expression were depleted together, these differences in
S phase population were no longer detectable compared to the control group (Fig. 7A).
This observation suggests that by affecting the p27 protein stability, Artemis can control
G1/S transition in normally proliferating cells.
In response to the absence of mitogenic signal, p27 protein is accumulated and cells
are arrested in a quiescent state. It has been well established that a down-regulation of
p27 protein level is required for these cells to re-enter the cell cycle. Based on my
results, I hypothesized that Artemis and DDB2 may control the cell cycle progression
upon serum starvation through p27. Again, Htert-RPE1 cells were used for the serum
starvation experiments. As indicated, these cells were well arrested in G0 after 0.1%
serum treatment for 24 hours (Fig. 7B, lane 1 and 2 in vector transfection). Consistent
with my previous observations, overexpression of Artemis or DDB2 destabilized p27,
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and therefore resulted in a higher S phase population in normally growing cells (Fig. 7B,
lane 1). After serum starvation for 24 hours, these transfected cells had almost 20 times
more S phase population compared to the vector control group, which was reflected by
the decreased amount of p27 protein (Fig 7B, lane 2).
In order to examine their response to serum withdrawal, RPE cells were kept in the
0.1% serum media for more than 24 hours as a part of my preliminary experiments. An
interesting observation is that when these cells were kept under low serum condition for
a prolonged period, they tend to adapt and re-enter the cell cycle (indicated by an
increased BrdU-incorporated population). This cell cycle reentry was paralleled with a
gradually decreased p27 protein level (Fig 7B, lane 3-5). This behavior gave us another
useful tool to examine my hypothesis since an up-regulated p27 level in these cells
should be able to block this re-entry. I treated the RPE1 cells with non-specific, Artemis
or DDB2 specific siRNAs. Next, cells were put into media containing 0.1% serum for
different periods of time. Cells in the control group demonstrated the ability to re-enter
into S phase after 36 hours of serum starvation, however in the Artemis or DDB2 siRNA
treated cells, this reentry was abolished and cells were kept arrested in G0 phase (Fig. 7C
lane 2-3). This observation appears to be correlated with an induction of p27 protein
level due to the Artemis or DDB2 depletion (Fig. 7C, lower panel). Taken together,
these results provide strong evidence to support the conclusion that p27 degradation
promoted by Artemis and DDB2 is involved in cell cycle regulation in normally growing
cells as well as in cells upon withdrawal of mitogenic signal.
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Figure 7. Artemis and DDB2 regulate cell cycle progression

Figure 7A. Depletion of Artemis causes a p27 dependent G1 arrest. hTert-RPE1
(hereafter RPE1) cells were transfected with Artemis and/or p27 specific siRNA or nonspecific (NS) siRNA as control. Forty-eight hours after transfection, BrdU was added to
label S-phase cells. Thirty minutes after incubation with BrdU, cells were harvested and
fixed. Upper panel: Cell cycle analysis was performed as stated in materials and
methods. Lower panel: Samples collected in the cell cycle analysis were subjected to
Western blot analysis to determine the levels of p27 and Artemis. Numbers in the panels
indicate the percentage of S phase cells.

Figure 7B. Artemis and DDB2 affect the G0-G1 transition via regulation of p27.
RPE1 cells were transfected with GST-Artemis or GST-DDB2 expressing constructs.
Thirty hours after transfection, cells were placed into DMEM F-12 media containing
0.1% FBS. Cells were harvested after the indicated incubation time. And 30 minutes
prior to harvest, BrdU was added into the media. Cell cycle profiles were collected by
flow cytometry after anti-BrdU and PI labeling. Cells stained positive for BrdU are
shown in the upper panel. Lower panel: Samples collected in the cell cycle analysis were
subjected to Western blot analysis to determine the level of p27.
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Figure 7C. Artemis and DDB2 affect the G0-G1 transition via regulation of p27.
Upper panel: RPE1 cells were transfected with Artemis or DDB2 specific siRNA, and
non-specific siRNA (NS) was used as control. Twenty-four hours after transfection cells
were washed with PBS and put into media containing 0.1% FBS for the indicated time.
BrdU was added into the culture 30 minutes before harvest. Cell cycle analysis was
performed as indicated in Fig. 7B. Lower panel: Samples collected in the cell cycle
analysis were subjected to the Western blot analysis to determine the level of p27.
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Artemis is regulated by its phosphorylation upon serum starvation

Artemis is involved in different cellular process such as NHEJ, V(D)J
recombination, and DNA damage-induced checkpoint regulation. These functions have
shown to be largely regulated by its phosphorylation by kinases such as ATM, ATR and
DNA-PKcs in response to different types of stress. My results here indicated that
Artemis has a role in controlling p27 degradation and cell cycle progression upon serum
starvation, I therefore speculated that this activity of Artemis could also be regulated by
its phosphorylation.
Different types of cellular stress, such as IR, UV, and MMC, have been shown to
induce phosphorylation of Artemis at various sites, however, it is still unknown if its
phosphorylation can also be triggered by serum starvation. Therefore, I tested Artemis
phosphorylation by gel shift mobility assay under this condition. As shown in Figure 8A,
Artemis was phosphorylated after cells were treated with 0.1% serum for 24 hours as
indicated by the its decreased mobility on the western blot. Pre-treatment with protein
phosphatase eliminated this mobility shift. Several serine sites on Artemis have been
identified to be phosphorylated, and phosphorylation specific antibodies toward some of
these sites were generated by our laboratoty. These reagents allowed me to search for the
site(s) that was phosphorylated in response to low serum condition. I examined
phosphorylation levels on 5 serine sites (S645, S516, S518, S534, S538) on Artemis
using the phospho-specific antibodies, and only phosphorylation at serine 645 was
increased upon serum withdrawal (Fig. 8B). S-to-A and S-to-D mutant of S645 were
generated and transfected into HeLa cells. In contrast to wild-type Artemis, an increased
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protein level of p27 was observed in cells overexpressing S645D, but not other mutants
of Artemis (Fig. 8C). Taken together, these results suggest that Artemis is
phosphorylated after serum starvation, and this modification impairs Artemis’s ability to
down-regulate p27, thereby allowing p27 protein to accumulate and cells to arrest in the
G0 phase. To test the latter statement, p27 protein levels were determined and cell cycle
profiles were analyzed in cells expressing either wild-type, S516/645A, or S516/645D
mutant. The double mutants were used here since no significant difference in cell cycle
profile could be detected by using single mutants. However, previous research in our lab
has shown that these two sites may be functionally related, and double mutants had an
enhanced effect in phenotype under different conditions (41, 48). A decreased p27
protein level was observed in wild-type or S516/645A Artemis transfected RPE1 cells,
resulting in an increased S phase population. Meanwhile, the p27 level was much higher
in S516/645D Artemis-expressing cells, and a larger G1 phase population was detected
compared to the wild-type and S516/645A cells (Fig. 8D). These results provide direct
evidence that the phosphorylation of Artemis has an inhibitory effect on its activity to
promote p27’s degradation, and thus leads to a p27-induced cell cycle arrest.
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Figure 8. Artemis is phosphorylated upon serum starvation.

Figure 8A. Artemis is phosphorylated upon serum starvation. RPE1 cells were grown
in media containing either 10% or 0.1% FBS for 24 hours prior to harvest. Upper panel:
Cell lysates were subjected to SDS-PAGE followed by Western blot using affinity
purified Artemis antibody. Artemis phosphorylation is indicated by a reduced mobility
band detected by the antibody. Lower panel: Artemis protein was immunoprecipitated
from cell lysates. Protein A-Sepharose beads with bound protein were incubated with 20
U of alkaline phosphatase at 30°C for 30 min. After washing, the proteins were eluted in
SDS sample buffer and separated by SDS-PAGE for immunoblotting using purified
Artemis antibody.

Figure 8B. Artemis serine 645 site is phosphorylated after serum withdrawal. RPE1
cells were transfected with GST-Artemis constructs. Twenty-four hours after
transfection cells were placed into DMEM-F12 containing either 10% or 0.1% FBS and
cultured for an additional 24 hours prior to harvesting in SDS sample buffer. Cell lysates
were subjected to immunoblot analysis using the indicated site-specific phospho-Artemis
antibodies.

Figure 8C. Artemis phosphorylation on Ser 645 negatively regulates p27
degradation. GST-tagged wild-type Artemis construct or Artemis constructs with
indicated mutations were expressed in HeLa cells. Forty-eight hours post-transfection,
cells were harvested and the amount of p27 was detected by immunoblot.
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Figure 8D. Artemis phosphorylation on Ser 645 affects cell cycle progression via
regulation of p27. RPE1 cells were transfected with GST-tagged wild type, S516/645A
or S516/645D Artemis constructs. Forty-eight hours after transfection, cells were
harvested and DNA was labeled by PI staining. Upper panel: Cell cycle profile was
obtained by flowcytometry analysis. Lower panel: Samples collected in the cell cycle
analysis were subjected to the Western blot to determine the protein level of p27.
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Artemis and DDB2 regulate p27 level in response to UV-irradiation

As a negative cell cycle regulator, the role of p27 in G1/S transition and cell cycle reentry has been well established. However, its regulation and function after DNA damage
is less understood.
It has been reported that Artemis can be phosphorylated on serine 645 and 516 by
ATR kinase in response to UV. In addition, my results showed that Artemis
phosphorylation can regulate its function in promoting p27 degradation. Therefore, I
next investigated the effect of UV-irradiation on p27 protein level. In Figure 9A, 293T
cells were treated with UV-C irradiation. Soon after the irradiation (1 hour), p27 protein
level was elevated, and this increase lasted for up to 4 hours post-UV. The UV-induced
accumulation of p27 protein was also observed in HeLa and U2OS cells (data not shown
here). In undamaged cells, ectopically expressed Artemis or DDB2 can promote p27
degradation, therefore, I examined if these proteins can also downregulate p27 level in
UV-damaged cells. As shown in Figure 9B and 9C, overexpression of Artemis or DDB2
not only caused a decrease of p27 level in untreated cells but also resulted in a decreased
amount of p27 upon UV irradiation. Moreover, consistent with the finding shown in
Figure 8, p27 was stabilized in both treated and untreated cells when the S645/516D
mutant of Artemis was overexpressed (Fig. 9C). Since these two serine sites on Artemis
are phosphorylated after UV, this observation suggests decreased Artemis function in
promoting p27’s degradation after UV. It is well known that p27 is one of the negative
regulators of the G1/S transition. The results shown here indicate that Artemis
phosphorylation after UV is responsible for a decreased E3 ligase activity targeting p27,
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and therefore, the stabilization of p27, which can contribute to UV-induced cell cycle
arrest.
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Figure 9. Artemis and DDB2 regulate p27 upon UV-irradiation.

Figure 9A. p27 protein level increases after UV exposure. 293T cells were treated
with 10 J/m2 or 20 J/m2 UV-C. After the indicated incubation time, cells were harvested
and p27 levels were detected by Western blot analysis.

Figure 9B. Artemis and DDB2 decrease p27 protein level in UV-irradiated cells.
293T cells were transfected with GST-Artemis, GST-DDB2 or GST-GUS constructs as
indicated. Forty-eight hours after transfection, cells were exposed to 10 J/m2 UV
radiation. After the indicated incubation time, cells were harvested and p27 levels were
determined by Western blot analysis.

Figure 9C. Phosphorylation of Artemis decreases its ability to promote the
degradation of p27 both before and after UV. 293T cells were transfected with wild type,
S516/645A or S516/645D Artemis constructs. Forty-eight hours after transfection, cells
were exposed to 10J/m2 UV-C. Cells were subsequently harvested in SDS sample buffer
after the indicated incubation time, and p27 levels were determined by Western blot
analysis.
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Artemis is a component of Cul4A-DDB1 complex

Artemis has previously been shown to interact with PIKKs such as DNA-PKcs,
ATM, and ATR, and to participate in multiple pathways including V(D)J recombination,
NHEJ, and cell cycle checkpoint responses. In this study, I have defined an entirely
novel function for Artemis as a component of the Cul4A-DDB1 E3 ligase complex.
Using mass spectrometry, an Artemis interacting-protein, DDB1 was identified.
Later, I confirmed this interaction in vivo. However, Artemis dose not interact with
DDB1 directly, but rather with DDB2. This observation indicates that the interaction
between Artemis and the DDB heterodimer is mediated by DDB2.
The DDB complex was first identified as damaged DNA binding proteins with
crucial functions in GGR-NER of UV-induced damage. However, UV or IR does not
affect the interaction between Artemis and DDB1. This observation is interesting for few
reasons. First, because Artemis has been shown to be extensively phosphorylated at
various sites after UV, my result indicates these phosphorylations are not essential for
this interaction, meaning that the Cul4A-DDB1-DDB2-Artemis complex assembly does
not require Artemis phosphorylation. Secondly, DDB2 protein is rapidly degraded after
UV; meanwhile, the interaction between Artemis and DDB1 remains unchanged.
Moreover, this unchanged interaction was also previously observed when DDB2
expression is depleted using specific siRNA (142). This raises the possibility that DDB2
is not the only factor mediating this interaction. One possible candidate is CSA. CSA is a
repair protein involved in TCR-NER pathway of UV-induced lesion. Similar to DDB2, it
directly associates with and acts as a substrate receptor in the Cul4A-DDB1 ligase. In
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contrast to DDB2, CSA dose not undergo degradation after UV. A direct interaction
between Artemis and CSA was reported previously in my master thesis. In addition to
CSA, another Cul4A-DDB1 interacting protein Skp2 has been shown to interact with
Artemis as well in this study. These results indicate that besides DDB2, both CSA and
Skp2 can bridge the interaction between Artemis and DDB1, and therefore, provide a
possible explanation for the unchanged interaction between Artemis and DDB1 after
UV, when DDB2 is degraded. Thirdly, DDB1 and Cul4A localize in both the cytoplasm
and the nucleus, and their association is unchanged regardless of DDB2 level (115). The
nuclear localization of both DDB1 and Cul4A depends on, but not solely, DDB2 (69,
115, 149). Upon UV irradiation, they translocate into the nucleus and bind tightly to the
damaged sites on chromatin (84). On the other hand, I previously observed that Artemis
localizes in both cytoplasm and nucleus, which is independent of UV damage. Since an
interaction between Artemis and DDB1 unaffected by UV is detected here, a further
investigation of the sub-cellular localization of this interaction before and after UV will
be necessary to explain this observation. It is possible that Artemis interacts with both
cytoplasmic and nuclear Cul4A-DDB1, in order to keep a stable association regardless
of UV. It is also a possibility that Artemis interacts with several different DDB1containing complexes, and these associations can be regulated differently by UV
treatment, which leads to an unchanged overall interaction with DDB1. As mentioned
above, DDB2 is required for the chromatin binding of DDB1 and Cul4A upon UV, it
will be interesting to examine if Artemis can also associate with these lesions as part of
the complex in a DDB2 dependent manner. Moreover, since it has been reported that the
nuclear localization of DDB1 in undamaged cells is dependent on DDB2 and Cul4B
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(84), I will like to investigate if these proteins can affect the Artemis subcellular
localization as well. The results of these future studies will provide important
information to further understand the importance and function of the interaction between
Artemis and DDB1. Since Artemis not only physically interacts with the DDB1
complex, but also regulates its associated E3 ligase activity, further localization studies
of Artemis can also be helpful in understanding its role in protein ubiquitylation
pathways and identification of more substrates.
Artemis was first identified as a putative endonuclease that in association with DNAPKcs cleaves DNA hairpin structures, a required step during the V(D)J recombination.
As a member of the SNM1 family, Artemis contains a conserved SNM1 domain, which
includes a metallo-β-lactamase fold and an appended β-CASP motif. The SNM1 domain
is thought to be essential for the nuclease activity of Artemis in association with DNAPKcs. However, in this study, the SNM1 conserved domain on Artemis is demonstrated
to serve as an interface to mediate the interaction with DDB. This finding is consistent
with our recently published results that hSnm1B/Apollo, another member of SNM1 gene
family, interacts with the endonuclease Mus81-Eme1, repair protein Mre11-Rad50-Nbs1
complex and microtubule binding protein Astrin via the SNM1 domain (150, 151).
Therefore, in addition to a hydrolase activity, the SNM1 conserved domain is also
essential for the ability of its family members to interact with different proteins, and
therefore, participate in various cellular pathways.
Besides DDB2, Artemis can also directly interact with p27, whose stability is
regulated by Artemis. A deletion mapping analysis on Artemis will be performed in
order to determine the required domain/sequence for this interaction. Even though the
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phosphorylation of Artemis has no effect on its interaction with the DDB complex, this
modification regulates it ability to promote the degradation of p27. Based on this
evidence, I speculate that the p27-interacting domain on Artemis is likely to be located
on C-terminal half that contains multiple (S/T)Q sites phosphorylated in response to
various types of stress, and that these phosphorylations can weaken its ability to interact
with p27. If the results of the GST pull-down assays using Artemis deletion constructs
and phospho-serine mutants support this speculation, then the interaction between
Artemis and the Cul4A-DDB1 complex can be described as follows. The N-terminal
conserved domain of Artemis is mediating its interaction with DDB2, hence the
interaction with the Cul4A-DDB1DDB2, meanwhile, the C-terminal phospho-sites are
required for its interaction with the substrate(s), which may be negatively inhibited by
Artemis phosphorylation. Although this model needs to be further investigated, my
results here strongly support a potential substrate-recruiting function of Artemis in the
Cul4A-DDB1DDB2 complex.
Like the SCF complex, the Cul4A-DDB1 E3 ligase also utilizes multiple substratespecific receptors to recruit its substrates. These receptors are DDB1 interacting proteins
(known as DCAF) that bridge the association between DDB1 and substrates. More than
50 different DCAFs have been identified, and majority of them are WD 40 proteins
containing a conserved WDXR motif. Although Artemis interacts with Cul4A-DDB1
and controls its activity toward p27, it is unlikely that Artemis has a function parallel to
DCAFs for the following reasons. First of all, Artemis does not directly interact with
DDB1, which is proved to be the case for all the known DCAFs. In addition, a motif
search of Artemis did not reveal any WD40 repeats or WDXR motifs that are found in
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the DCAFs. Moreover, in my study Artemis is found to interact with two of the DCAFs,
DDB2 and CSA, as well as the substrate p27; and both Artemis and DDB2 are required
for p27 degradation. Taken together, this evidence suggests that Artemis is more likely
acting as an additional factor for p27 degradation by Cul4A-DDB1DDB2. Actually,
several published results support the concept that additional factor is needed for the
recruitment of substrates by CRL. For example, it has been established that SCFSkp2
requires the presence of Cks1 to target the ubiquitylation of p27(152, 153) . Cks1
interacts with the T187 phosphorylated p27, which is essential for the F-box protein
Skp2 to interact with p27. Another example of such a factor has been reported for
Cul4A-DDB1Cdt2 complex, a ligase responsible for the degradation of both Cdt1 and
p21. In both cases, direct interactions between the substrates and PCNA are needed for
the Cul4A-DDB1Cdt2 to interact and ubiquitylate p21 and Cdt1 (102, 108). In line with
these results is my observation that Artemis interacts with both DDB2 and p27, which
leads me to the speculation that Artemis is functioning in the Cul4A-DDB1DDB2 like
Cks1 and PCNA in SCFSkp2 and Cul4A-DDB1Cdt2, respectively. Nevertheless, in order to
confirm this hypothesis an Artemis-dependent interaction between DDB2 and p27 needs
to be examined.
Multiple phosphorylation sites on Artemis have been identified, however, the role of
these modification in Artemis function remains largely undefined. Although earlier
studies suggest that phosphorylation of Artemis, especially by DNA-PKcs, is important
for its endonuclease activity and V(D)J recombination (154-156), Artemis mutants
defective in DNA-PKcs interaction are capable of rescuing V(D)J defect in Artemis
deficient cells (38). Moreover, reports from our laboratory and several other groups
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showed that mutations at multiple phosphorylation sites of Artemis do not affect its
endonuclease activity and ability to rescue V(D)J recombination; instead, they cause
defects in the recovery from damage-induced cell cycle checkpoints (38, 41-43, 48,
157). These observations imply that the phosphorylation of Artemis dose not play a
major role, if any, in regulating its nuclease function, but rather in other cellular
pathways. My results here show that its phosphorylation can affect the stability of p27
protein, a substrate of Cul4A-DDB1DDB2, suggesting a possible function of Artemis
phosphorylation in controlling E3 ligase activity. This notion is also supported by a
recent finding from our laboratory that the phosphorylation of Artemis regulates S phase
checkpoint recovery by promoting the degradation of cyclin E (48). As mentioned
above, it is possible that Artemis phosphorylation modulates its interaction with different
substrates, or it may be a possibility that this modification can regulate the ligase activity
without affecting its ability to interact with the substrates. The mechanism of how the
phosphorylation regulates Artemis function in protein’s ubiquitylation is currently under
investigation in our laboratory.

Artemis and DDB2 regulate the degradation of p27 through the Cul4A-DDB1
complex

As a CDK inhibitor, p27’s protein level, localization and activity are mainly
regulated through post-translational modification. SCFSkp2 and KPC1/2 are two wellestablished E3 ligases promoting the degradation of p27. These two complexes are
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distinct, with SCFSkp2 functioning in the nucleus and targeting p27 phosphorylated by
Cdk2/Cyclin E at Thr187 during S/G2 phase, while the cytoplasmic KPC1/2
ubiquitylating p27 that is exported from the nucleus upon serine 10 phosphorylation
during the early G1 phase. Recent studies indicate a possible involvement of Cul4ADDB1 in p27 degradation. My results presented here not only confirm these previous
findings, but also reveal that both Artemis and DDB2 are part of the complex, and that
they are required for p27 degradation via the Cul4A-DDB1 complex. These observations
provide direct evidence to support the hypothesis that in complex with Artemis Cul4ADDB1DDB2 (Cul4A-DDB1DDB2-Artemis) can function as the third E3 ligase responsible for
p27 ubiquitylation. As shown in my in vivo ubiquitylation assay, overexpression of
Artemis or DDB2 can promote the ubiquitylation of p27. Interestingly, Thr to Ala
mutations of p27 on Thr187 and Thr157 do not affect the level of ubiquitylation
compared to wild-type p27. Several conclusions can be drawn from this result. i) Thr187
on p27 can be phosphorylated by Cdk2/Cyc E, and this modification is a prerequirement for its degradation by SCFSkp2. However, this is not true for Artemis
promoted p27 ubiquitylation, implying that an Artemis-containing Cul4A-DDB1
complex can target p27 for degradation during early G1 phase even when Cdk2/Cyclin E
is not yet activated. ii) Thr157 is located within the NLS (nuclear localization signal) of
p27, and phosphorylation of Thr157 by AKT results in cytoplasmic sequestration of p27.
Artemis can effectively promote the ubiquitylation of nuclear localized T157A mutant of
p27, suggesting that Cul4A-DDB1DDB2-Artemis has activity toward nuclear p27. In contrast
to KPC1/2, which ubquitylates cytoplasmic p27 during G1 phase, Cul4A-DDB1DDB2Artemis

can target p27 in the nucleus during this same phase of cell cycle. Furthermore, the
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protein level of DDB2 is cell cycle regulated, and is high during early G1 to the G1/S
boundary (74). This finding also supports a DDB2-required ligase activity toward p27
during G1 phase.
Why do cells need a third ligase to degrade p27? As a member of Cip/Kip family
member, p27 can bind and inhibit Cdk2. p27 level is high in G0 phase, which is
concomitant with low Cdk activity. p27 protein level decreases through the ubiquitinproteasome pathway when cells re-enter the cell cycle and progress to S phase, thereby
allowing the activation of Cdk kinase. Cdk2 can phosphorylate p27 at Thr 187, which is
then recognized and ubiquitylated by SCFSkp2. Nevertheless, p27 inhibits the activity of
the very kinase that activates it, and p27 degradation precedes the activation of Cdk2.
Moreover, Skp2 is not expressed until late G1 phase, and Skp2-/- cells exhibit normal
G0-G1 progression and p27 degradation (139, 158). All this evidence indicates that a
SCFSkp2-independent p27 degradation pathway(s) is employed by cells, and this
speculation led to the later discovery of the KPC1/2 complex (139). Upon cell cycle reentry, p27 can be phosphorylated on serine 10 by KIS kinase (131). This
phosphorylation signals the nuclear export of p27, and then cytoplasmic p27 is
ubiquitylated and degraded by KPC1/2. The subcellular redistribution and the
subsequent degradation decrease p27 level in the nucleus, thereby relieving the
inhibitory effect on the Cdk2 to permit its activation, which facilitates SCFSkp2 mediated
p27 degradation. However, only a fraction of p27 is phosphorylated on serine10 and
translocated into the cytoplasm in the early G1 phase. In addition, nuclear retained p27
can still be degraded independent of serine 10 phosphorylation (158). Therefore, the
existence of another E3 ligase in the nucleus to downregulate p27 level is not unlikely.
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This new pathway may have an additive yet not redundant function compared to
KPC1/2, and thus keep p27 levels low enough in the nucleus for the activation of Cdk2
and the subsequent degradation by SCFSkp2. My research here provides important
information to support that Cul4A-DDB1DDB2-Artemis is one of the candidates functioning
to fulfill this role. It works as a Thr187-independent pathway in the nucleus to decrease
p27 protein level, thereby triggering subsequent biological events and promoting cell
cycle progression.
It has been reported that Cul4A-DDB1Cdt2 is responsible for the degradation of Cdt1
and p21 during S phase and after UV irradiation. Meanwhile, these proteins also undergo
SCFSkp2-mediated degradation in undamaged cells, suggesting overlapped but not totally
redundant functions between SCFSkp2 and Cul4A-DDB1. This statement is further
supported by the results shown in this work. I found that in addition to SCFSkp2, p27 can
also be degraded by Cul4A-DDB1DDB2-Artemis, and this pathway appears to function in
early G1 phase in the nucleus as well as after UV irradiation.
However, there are still several questions that remain to be examined. The stability
of p27 is mainly regulated by ubiquitin-mediated degradation, and its phosphorylations
play an important role in this pathway. Here, I revealed that such modifications of
Thr157 and Thr 187 are not required for its degradation by Cul4A-DDB1DDB2-Artemis.
However, there are multiple other sites on p27 that can be phosphorylated by various
kinases, some of which control subcellular redistribution (e.g. Thr 198, Ser 10), while
others are of undetermined function (e.g. Try 88). Therefore, additional studies will be
needed to determine if any of these sites are required for Artemis-promoted p27
proteolysis. One of the sites that will be included in our future study is Y88. This site can
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be phosphorylated by nonreceptor tyrosine kinase Lyn and Abl rapidly after mitogen
stimulation, and this modification can decrease the protein stability of p27 and increase
its phosphorylation on Thr187 (159, 160). Although degradation by SCFSkp2 due to
increased T187 phosphorylation is thought to be responsible for the decreased protein
stability in this case, as I mentioned above, SCFSkp2 works at a later cell cycle stage,
indicating the possibility that another ligase (maybe Cul4A-DDB1DDB2-Artemis) has a
function in this tyrosine phosphorylation-regulated pathway. p27 can bind with
Cdk2/Cyclin E to form an inhibitory complex during G0/G1. It will be interesting to
understand how Cul4A-DDB1DDB2-Artemis physically targets p27 in this inhibitory
complex. There are several possibilities. For example, the interaction between p27 and
Artemis can compete with its association with Cdk2; or modifications such as
phosphorylation of p27 results in a conformational change, making it a better substrate
for the Cul4A-DDB1 ligase. Further structural and phosphorylation sites studies will
provide information to define the exact mechanism of how Cul4A-DDB1DDB2-Artemis
targets p27 for degradation.

Artemis plays a role in cell cycle regulation through p27

p27 degradation is essential for mitogen-induced cell cycle re-entry and G1/S
transition. The findings that Artemis and DDB2 regulate p27 stability led us to examine
the function of these two proteins in controlling cell cycle progression.
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G0 phase is characterized by a higher p27 level and a lower Cdk activity. RPE1 cells
were employed in my cell cycle studies. This is an untransformed diploid and
nontumorigenic primary human epithelial cell line, and as shown in my results were well
arrested at G0 phase within 24 hour upon serum withdrawal. However, an impaired
arrest was observed in cells with overexpression of Artemis and DDB2, consistent with
the concomitant lower p27 levels. Although Artemis has been shown to control p53
stability (49), p27 is the major effector for G0 arrest upon serum withdrawal (124). Thus,
based on these results we speculated that the Artemis-mediated p27 degradation pathway
plays a role in cellular responses upon serum starvation. p27 is stabilized during G0
phase, and its stabilization is controlled by its phosphorylation on serine 10 by the Mirk
kinase involved in the MAP kinase pathway (161). In contrast to the serine 10
phosphorylation by KIS that targets p27 for nuclear export during the G1 phase, this
phosphorylation in G0 phase is responsible for its stabilization in the nucleus.
Interestingly, Artemis is also phosphorylated at the same time. Moreover, Artemis
phosphorylation leads to an increased p27 protein level as well. These observations help
us to further understand the mechanism of p27 stabilization in the G0 phase. Cul4ADDB1DDB2-Artemis can target p27 for degradation in normally progressing cells. Upon
serum withdrawal, a series of signal transduction events trigger the phosphorylation of
Artemis on serine 645 site. This modification has an inhibitory effect on Artemis’s
ability to promote the degradation of p27 by Cul4A-DDB1DDB2-Artemis, and as a result,
p27 protein levels increase. In addition, p27 is also phosphorylated at its serine 10 site,
which further stabilizes its protein level. Hyperphosphorylation on serine 645 on
Artemis has been reported after UV or IR treatment by ATR and ATM, respectively, yet

90

this is the first report showing that this phosphoryltion can also be induced by serum
withdrawal. The kinase responsible for this modification needs to be defined in the
future. Nevertheless, the Mirk kinase will make a good candidate to be tested, since it
can also phosphorylate p27 on serine 10. And this would be a more efficient mechanism
for cells to regulate two events that have the same consequence under the same condition
(serum starvation) by one kinase. We are currently planning on testing this hypothesis by
checking Artemis phosphorylation and its ability to downregulate p27 by using specific
inhibitors of kinases involved in the Mirk pathway. Another possibility we would like to
investigate is whether the phosphorylation on p27 serine 10 can affect its degradation by
Cul4A-DDB1DDB2-Artemis. The reason for this hypothesis is that p27 phosphorylated at
serine 10 is not only stabilized during G0 phase, but is also stabilized during G1 phase in
the nucleus (132).
Upon mitogen stimulation, p27 protein level is downregulated and therefore cells are
able to re-enter the cell cycle. Although RPE1 cells can be well arrested after 24-hours
of serum starvation, these cells tend to re-progress into the next cell cycle after
prolonged time. Although we do not understand how these cells become adapted to the
low serum stress, this phenotype gave us a tool to examine the effect of Artemis or
DDB2-mediated p27 degradation on cell cycle reentry, an event associated with a
decreased p27 level. Without Artemis or DDB2 an impaired cell cycle re-entry was
observed, indicating that the degradation of p27 mediated by Cul4A-DDB1DDB2-Artemis is
required for this progression. Taken together with the phosphorylation of Artemis
triggered by low serum, I hypothesized that a kinase activity specific to serum
withdrawal phosphorylates Artemis, which leads to a decreased Cul4A-DDB1DDB2-Artemis
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ligase activity and a stabilized p27 level. However, after mitogen stimulation or in
normally growing cells, Artemis is not phosphorylated or its phosphorylation pattern
changes, allowing a re-activation of Cul4A-DDB1DDB2-Artemis complex to maintain a low
p27 protein level that is essential for the cell cycle re-entry and progression. In order to
confirm this hypothesis, the phosphorylation and dephosphorylation kinetics of Artemis
in response to serum withdrawal and mitogen stimulation will be examined. Artemis
may be dephosphorylated when the signal triggered by the growth factor depletion is
removed, however, as I mentioned above, de-phosphorylation is not the only possibility,
Artemis may also be phosphorylated at different sites in response to mitogen stimulation,
which in turn upregulate the ligase activity. Phospho-specific Artemis antibodies on
multiple sites have been developed by our laboratory, I will use these reagents to
investigate the cell cycle specific phosphorylation pattern of Artemis at multiple sites. If
the any of these phosphorylations are found to be cell cycle regulated or mitogen
dependent, then mutations at these sites will be generated. These Artemis mutants will
be further tested for their abilities to promote p27 degradation. Because mitogen
exposure can activate various kinases to phosphorylate p27, I will exam whether newly
identified phosphorylation sites on Artemis are substrates for these kinases.
A decreased p27 is essential for the activation of Cdk2/Cyclin E complex, and
therefore the G1/S transition. Depletion of Artemis expression in normally growing
RPE1 cells resulted in a G1 arrest, indicating its involvement in this transition. Although
Artemis also has a role in regulating p53 stability, this G1 arrest has also been observed
in p53 null cells previously by our laboratory (data not shown). In addition, when p27 is
depleted together with Artemis, similar cell cycle profile is detected compared to normal
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cells, suggesting that the observed G1 arrest in Artemis depleted cells was due to the
resultant increased p27 levels in these cells. These findings not only confirm the function
of Cul4A-DDB1DDB2-Artemis in promoting p27 degradation that is essential for cell cycle
progression in normally proliferating cells, but also provide information to link this
ligase activity toward p27 to the previously reported function of DDB in controlling the
G1/S transition. In addition to participating in the NER pathway for UV-induced DNA
damage, a transactivation regulatory activity of DDB has also been reported (162).
DDB2 can bind to transcription factor E2F1, which induces the expression of genes such
as cyclin E that are responsible for progression into S phase. In association with DDB1,
DDB2 can stimulate the E2F1-dependent transcription, therefore facilitating the G1/S
transition (63, 74). My results here provide an additional explanation to this previous
observation. p27 can inhibit the E2F1 transactivation activity by inhibiting Cdk2 activity
and increasing the inhibitory E2F1-p130 complex, thereby negatively regulating the
G1/S transition . In complex with Cul4A and Roc1, DDB1 and DDB2 form an active
ligase complex that utilizes Artemis as a substrate-specific receptor to target p27 for
degradation, which results in increased Cdk2 and E2F1 activity. Furthermore, the DDB
heterodimer can directly upregulate the E2F1-dependent transcription of genes required
for S phase entry. These two pathways positively enhance each other, and together with
the Skp2-dependent p27 proteolysis, facilitate the G1/S transition.

Artemis regulates the stability of p27 in response to UV-irradiation
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The roles of p27 in controlling G0-G1 and G1-S transitions have been extensively
studied. However, as a Cdk inhibitor, p27’s function in cellular response to DNA
damage is largely undefined. Several reports have shown a different response in p27
protein level upon UV-irradiation varying from increased to unchanged to decreased
protein levels, depending on the cell type, UV wave length, and UV dose used in the
individual study (67, 163-167). In my study here, an increased p27 protein level has been
detected in 3 different cell lines after UVC treatment. Although these results are still
preliminary, they provide important information for us to understand the cell cycle
regulation after UV-induced damage.
After IR irradiation, an upregulated p53 level and the subsequent increased p21 level
is involved in cell cycle arrest. Nevertheless, accumulated evidence suggests that p21 is
degraded by a PCNA-dependent Cul4A-DDB1Cdt2 mediated pathway rapidly after low
dose UV irradiation. This degradation is thought to facilitate repair of the UV-induced
DNA damage, since p21 binds to PCNA and inhibits its activity in gap-filling DNA
synthesis. Nevertheless, cell cycle progression is arrested upon UV treatment to allow
the efficient repair of DNA damage even though p21 has undergone proteolysis. Based
on the findings in this study, I speculate that the regulation of p27 stability by Cul4ADDB1DDB2-Artemis is involved the control of cell cycle arrest after UV. Upon UV
treatment, Artemis is phosphorylated at multiple sites, including serine 645, by the ATR
kinase. The phosphorylation on serine 645 of Artemis has a negative effect on its activity
to promote p27 degradation, which in turn stabilizes p27 in response to UV damage.
Moreover, Cul4A-DDB1DDB2 can also target DDB2 for degradation after UV, which will
further arrest the cell cycle progression by two means. First, DDB2 is required for the
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Cul4A-DDB1 mediated p27 ubiquitylation, therefore, the removal of DDB2 from the
nucleus after damage will stabilize p27 in order to inhibit Cdk1/2 activity. Secondly, the
degradation of DDB2 will prevent its enhancement of E2F1 transcriptional activity,
which can also contribute to the cell cycle arrest. The mechanism of how p27 stability
regulated by Cul4A-DDB1DDB2-Artemis controls the UV-induced cellular response is
currently under investigation in our laboratory.

Artemis as a component of Cullin-based E3 ligases

As discussed above, I have found that Artemis is a component of the Cul4ADDB1DDB2 ubiquitin ligase complex and regulates the degradation of p27. In addition,
my results also demonstrate that Artemis can directly interact with Skp2 and Cul1,
which are components of the Cul1-based SCF ligase complex. Although it was
suggested that Skp2 could be utilized by Cul4A-DDB1 complex for p27 ubquitylation,
no association between Cul1 and DDB1 was reported, therefore, the association with
Cul1 more likely indicates Artemis’s involvement in the Cul1-based complex. A recent
report from our laboratory also showed a direct interaction between Artemis and Fbw7,
another substrate recruiting F-box protein for the SCF complex (48). Taken together, this
evidence suggests that Artemis has a generalized function involved in Cullin-based
ligase activity regulation that is not limited to Cul4A-DDB1. This role of Artemis may
be one of its essential functions, and may explain the multiple pathways in which this
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protein appears to participate. One of our current research focuses is to further explore
the mechanism of how Artemis functions in Cullin-based E3 ligases.
As mentioned above, Artemis directly interacts with 2 DCAFs proteins, DDB2 and
CSA, and 2 F-box proteins, Skp2 and Fbw7. The substrates they target include Cdt1,
DDB2, CSB, XPC, H2A, H3, H4, p21, c-myc, and many others. Although I showed that
Artemis does not affect the degradation of Cdt1 after UV, its ability to regulate the
stabilities of the other substrates is worth investigating. In addition, I will also evaluate
the interaction between Artemis and other DCAFs or F-box proteins. DDB1 is known to
interact with both Cul4A and Cul4B. While the Cul4B-DDB1 complex is less
understood, it appears to have some overlapped yet not redundant functions compared to
Cul4A-DDB1 (115, 168). It will be interesting to determine if Artemis has any
involvement in the Cul4B-DDB1 ligase complex. These results will lead us to the
identification of additional substrates that are regulated by Artemis, and provide us
information to further understand its function in the Cullin-based ligase.

Significance

Artemis was first identified as the causative gene for a subset of SCID patients with
defective V(D)J recombination. Earlier studies have shown that its major function is to
act a nuclease in V(D)J recombination and NHEJ repair. Recent findings from our
laboratory have demonstrated new functions for Artemis that is beyond a nuclease,
including controlling DNA damage checkpoint responses, and regulating cellular
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response to oxidative stress through p53. My research here defines a novel function of
Artemis as a component of Cul4A-DDB1DDB2 to regulate p27 stability. It is also the first
report showing the involvement of DDB2 as the linker in Cul4-DDB1 mediated p27
degradation. In addition, a role for Artemis in cell cycle regulation in normally
proliferating cells and serum-starved cells is also demonstrated. These observations
suggest that by regulating Cullin-based ubiquitin ligase activities, and thereby affecting
the stabilities of various substrates, is one of the common mechanisms by which Artemis
participates in various biological pathways.
The negative cell cycle regulator p27 is an atypical tumor suppressor that regulates
cell proliferation, apoptosis and cell motility. It has been reported that inactivation of
Skp2 in mice, a negative regulator of p27, can suppress tumorigenesis by inducing
senescence specifically in cancer cells but not normal cells (169). Taken together with
my results showing that Artemis can downregulate p27 and interact with Skp2, I
speculate that Artemis can be used as a potential target for cancer treatment. Moreover,
since Artemis is also a negative regulator of p53, targeting Artemis may be more
efficient than Skp2. Although Artemis has been shown to be a repair factor involved in
the NHEJ, that is unlikely to conflict with its potential effects on tumorigenesis. In
normal cells, Artemis is required for cell cycle progression through degradation of p27.
Upon DNA damage, it has functions in cell cycle arrest, maintenance of DNA repair
checkpoints and participating in NHEJ. However, under the specific genetic
backgrounds of cancer cells, Artemis’s ability to downregulate proteins such as p27 and
p53 may contribute to tumor development. Furthermore, it is likely that Artemis is
deregulated in cancer cells, and either the overexpression or mutations on the
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phosphorylation sites of Artemis can largely affect the protein stabilities of its
downstream targets such as p27 and p53. p27 is downregulated in many cancers and its
low level is usually associated with a poor prognosis. In order to explore the effects of
Artemis’s disruption on tumorigenesis, we would like to check the expression levels of
Artemis in different types of cancer samples, and later we will also establish mouse
models to further investigate this hypothesis.
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10A

10B

Figure 10A. Model depicting Artemis and DDB2 as components of the Cul4ADDB1 E3 ligase complex that targets p27 for degradation. DDB2, a DCAF protein,
functions as a receptor in this ligase complex. Artemis directly interacts with DDB2 and
p27, and is an additional factor required for the ubiquitylation of p27 by Cul4ADDB1DDB2.

Figure 10B. Schematic depicting the roles of Artemis in cell cycle control via
regulation of Cul4A-DDB1-mediated p27 degradation. In normally growing or mitogen
stimulated cells, Artemis, as a component of Cul4A-DDB1DDB2-Artemis, promotes p27
ubiquitylation and degradation, which facilitates cell cycle re-entry and progression.
Upon serum starvation or UV-irradiation Artemis is phosphorylated, which impairs its
activity to promote the degradation of p27, which results in p27 stabilization and cell
cycle arrest. Cul4A-DDB1Cdt2-PCNA targets p21 for degradation after UV, thereby
relieving its inhibitory effect on PCNA and facilitate the NER.
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